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Preface
Respiratory syncytial virus (RSV) causes seasonal epidemics during the winter 
and wet seasons, particularly in young children. Of the children infected with RSV, 
70%–90% are diagnosed with bronchiolitis and hospitalized because they need 
supplemental oxygen. Approximately 1% of healthy young infants are hospitalized 
during the first RSV season due to severe lower respiratory tract infection. Three to 
ten times higher rates of RSV have been reported in high-risk populations, includ-
ing preterm infants; those with bronchopulmonary dysplasia; infants and children 
with congenital heart disease, cystic fibrosis, congenital diaphragmatic hernia, neu-
romuscular disease, or Down syndrome; and immunocompromised infants. After 
two RSV seasons and three years of age, nearly 100% of children have experienced 
an RSV infection or have antibodies against RSV. However, despite neutralizing 
antibodies, recurrent infections do occur. Severity of disease, though, decreases as 
children become older.
For the last 20 years, palivizumab has been used for immunoprophylaxis of RSV 
infections. It is a monoclonal antibody that binds to the F-glycoprotein that is 95% 
identical between the G- and F-receptor and thus works against RSV types A and B. 
Palivizumab is given to high-risk infants only, hence the burden of RSV diseases 
continues to grow and a vaccine is urgently needed.
Following a fatal vaccine trial in the early 1960s that led to two deaths, many efforts 
to develop a safe vaccine have been undertaken. This book covers the problems the 
young RSV patient faces and provides data on the most recent vaccine progresses 
and new monoclonal antibodies. It is our hope that this volume will open up new 
avenues to future tools in RSV prophylaxis.
Palivizumab (Synagis®, MedImmune, Inc., USA) is a humanized monoclonal anti-
body that provides immunoprophylaxis against respiratory syncytial virus (RSV). 
RSV causes seasonal epidemics (winter or wet-season) of serious lower respiratory 
tract infections in young infants with subsequent increased frequency of recurrent 
wheezing during early childhood. Two large, double-blind, placebo-controlled 
trials including infants at high risk for severe RSV infection showed significant 
reduction of RSV-related hospitalizations: a 55% reduction in 1502 infants with 
prematurity and/or bronchopulmonary dysplasia and a 45% reduction in 1287 
infants with hemodynamically significant congenital heart disease. Palivizumab 
proved to be as safe as an intramuscular injection of 15 mg/kg every 30 days for 
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Disease Severity in Respiratory 
Syncytial Virus Infection: Role of 
Viral and Host Factors
Julian P. Legg
Abstract
Respiratory syncytial virus (RSV) is not only a major cause of severe lower 
respiratory tract infection (LRTI) in infancy but is increasingly recognised as an 
important pathogen in later life. RSV infection is associated with a wide spec-
trum of disease ranging from asymptomatic infection to life-threatening bron-
chiolitis and pneumonia. Research has demonstrated that there exists a complex 
interplay between viral and host factors that determines the severity of disease 
following RSV infection. Several factors determine RSV virulence including the 
infective properties of individual strains and viral load (VL). Disease outcome 
from RSV infection is also impacted considerably by a variety of host factors 
with the host immune response increasingly recognised as pivotal. This chapter 
outlines our current understanding of these factors and provides an oversight of 
their relative importance.
Keywords: respiratory syncytial virus, disease severity, viral load, immunology, 
genotype
1. Introduction
Respiratory syncytial virus (RSV) has long been recognised as a cause of severe 
lower respiratory tract infection (LRTI) in early childhood with increasing evi-
dence of its role as an important pathogen in later life [1]. RSV has many intriguing 
features including its worldwide distribution, its capacity to cause severe disease in 
early childhood and its extended impact on respiratory health [2]. Consequently, 
RSV has been the focus of comprehensive study including host and viral determi-
nants of disease severity.
Serologic data has demonstrated that a high proportion of children (between 
50 and 70%) will be infected with RSV in the first year of life [3, 4]. Asymptomatic 
infection is infrequent during infancy with most infants developing clinical features 
of an upper respiratory tract infection alone [5]. Following an initial prodromal 
URTI phase, 25–40% of those infected will progress to develop signs and symp-
toms of bronchiolitis with tachypnoea and chest recession [5]. Bronchiolitis is 
usually a mild illness in most infants, but a small proportion (2–3%) will develop 
severe bronchiolitis necessitating hospitalisation [6]. It has been estimated that 
nearly 33.8 million new cases of RSV-associated LRTI occur worldwide in children 
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under 5 years of age leading to approximately 3.4 million hospitalizations annually 
[7]. Mortality from RSV infection in developed countries is rare during infancy 
although there are an estimated 66,000 and 239,000 yearly deaths in children 
younger than 5 in the developing world [7, 8].
The major clinical manifestation of RSV in older children and adults is upper 
respiratory tract illness (rhinitis and acute otitis media) although symptoms tend 
to last longer and there is an increased incidence of cough and wheeze compared to 
other respiratory viral infections [9, 10]. Immunity following RSV infection is only 
effective for a matter of months before the individual is once again susceptible to 
reinfection [11]. Consequently, reinfection occurs throughout life. LRTI is unusual 
although RSV accounts for a significant percentage (>4%) of community-acquired 
pneumonias during epidemics [12]. Elderly adults have an increased risk of lower 
respiratory tract involvement, with 30–40% of patients having auscultatory find-
ings on examination of the chest [13].
RSV is evidently associated with a wide spectrum of disease which has led 
to significant interest into those factors that determine the nature of the clinical 
response to infection. Host, viral and geographical factors interact to dictate the 
clinical outcome of any viral infection. The viral and host factors that influence the 
human response to RSV infection are the focus of this chapter.
2. Viral factors
2.1 The virus
Respiratory syncytial virus is a medium-sized (120–300 nm), enveloped, single-
stranded RNA virus of the Paramyxoviridae family that is a ubiquitous pathogen in 
all age groups. In 1956, it was first isolated from upper respiratory tract specimens 
collected from a chimpanzee with coryza [14], being subsequently recovered from 
two children in Baltimore with lower respiratory tract disease [15]. Its identification 
as a principal cause of bronchiolitis took a further 4 years [16].
2.2 Viral genome and proteins
RSV has a negative polarity RNA genome composed of 15,000 nucleotides with 
an estimated weight of 500 kDa. The non-segmented RNA genome encodes 10 units 
from which 11 proteins are translated. The RSV nucleocapsid core consists of the 
viral genomic RNA wrapped with N protein (called the N-RNA template), the major 
viral phosphoprotein, encoded by the P gene and the major subunit of the RNA-
dependent RNA polymerase, encoded by the L gene. The genome also encodes for 
two matrix proteins. The first matrix protein, M, is essential for RSV replication and 
passaging and plays a central role in virus assembly. The second matrix protein, M2, 
is localised within the nucleocapsid and has an essential role in the production of 
complete mRNA during replication. The NS1 and NS2 gene sequences encode for the 
so-called nonstructural proteins which have been shown to have multiple functions 
including abrogation of the cellular antiviral response and induction of interferon 
(IFN) transcription.
Three surface proteins are also encoded within the RSV genome, the fusion (F) 
protein, the G attachment (G) protein and the small hydrophobic (SH) protein. The 
F protein plays a central role in virus entry. It mediates fusion between the viral and 
cellular membrane, thereby allowing the nucleocapsid to enter the cytoplasm of 
the host cell. The G protein is essential for initial RSV attachment and interaction 
with the host cell and is important for in vivo replication. The SH protein is a short 
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integral membrane protein that is not essential for RSV replication in cell culture 
but is involved to some degree in RSV survival in vivo.
2.3 Viral load
The estimation of viral load (VL) has proved invaluable for predicting disease 
outcome in viral infections such as hepatitis C [17] and HIV [18]. The relationship 
between the quantity of RSV in respiratory tract specimens and disease severity has 
been the focus of multiple studies over the last 30 years. There has been significant 
variability in study findings to date, with some identifying a positive correlation 
between viral load and severity [19–21], while others have found no significant cor-
relation [22, 23] or an inverse relationship [24]. These disparate outcomes are likely 
related to the variable nature of the studies with significant differences in age range, 
enrolment criteria, quantification techniques (plaque assay vs. PCR) and timing 
of sample collection. The majority of studies have evaluated VL in hospitalised 
children only and at a single time point.
A number of recent studies have investigated the dynamics of viral load through 
the analysis of sequential specimens collected during the course of the illness. 
Garcia-Maurino et al. studied 150 children <2 years of age (39 outpatients and 
111 inpatients) over 2 successive winters [25]. Children who required hospitalisa-
tion had significantly lower VLs assessed using quantitative PCR on nasal swabs. 
Sequential VL evaluation (only evaluated in those hospitalised) demonstrated 
higher initial VLs and a faster VL decline in those requiring ward care only 
compared to those requiring PICU care. These findings are consistent with the 
results from a smaller study of 33 infants hospitalised with RSV bronchiolitis 
using nasosorption sampling of the upper airway [26]. Faster viral clearance was 
also associated with milder disease and a shorter length of stay in 219 children in 
Boston with RSV infection whose upper airway VL was assessed using plaque assay 
[27]. However, by contrast, higher VLs on day 3 of admission were associated with 
increased disease severity requiring PICU admission.
Studies to date highlight the complexity of the interaction between VL and 
disease severity. Further studies are required to clarify this relationship and 
should ideally analyse sequential specimens for changes in viral load in a tightly 
defined cohort of children and include both hospitalised and community infants 
with mild disease.
2.4 Genetic and antigenic variability
Through the application of monoclonal antibody technology, two major antigenic 
groups of RSV have been identified—the A and B subgroups [28]. Epidemiological 
studies have revealed that these groups have existed for over 40 years and have a 
worldwide distribution [28]. Both groups appear to circulate concurrently with 
geographical and temporal clustering frequently reported [29, 30]. The prevalence 
of each subgroup follows an irregular, alternating pattern with subgroup A pre-
dominating in most analyses [29]. The link between the major antigenic groups of 
RSV and disease severity is unclear. RSV-A has been associated with a more severe 
disease course in a number of studies [31–33], while others have identified no dif-
ference between the subgroups [34–37] or increased severity due to infection with 
RSV-B [38, 39]. While these inconsistent findings could result from differences in 
study design and geography, the presence of varying RSV genotypes is likely to be a 
significant confounding factor.
The RSV genome demonstrates significantly more variability than previously 
understood [1].
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The G protein has been demonstrated as the greatest source of intragroup 
variability with nucleotide differences of up to 20% [40]. These differences reside 
predominantly within two variable regions that flank a relatively conserved central 
ectodomain of the G protein gene.
The single-stranded, non-segmented nature of the RSV genome precludes the 
genetic rearrangements that typify the dramatic antigenic shifts of the influenza 
virus [41]. However, there is a considerable potential for genomic mutation given 
the inability of RNA polymerase to proof-read during replication of the genome. 
This provides an opportunity for antigenic drift to occur under the influence of 
selective pressures from the environment. The current variability of the G protein 
between RSV strains may therefore be explained by the progressive accumulation of 
change together with survival and extinction of particular genotypes [42].
Prior to whole-genome sequencing, genetic studies have assessed strain vari-
ability within the two major groups primarily through analysis of the G protein gene 
[42, 43]. Subsequent phylogenetic analyses have identified multiple lineages within 
both group A and group B viruses with marked similarities observed between 
strains from different locations and time periods [29, 42, 44]. This has led to the 
recent subclassification of RSV into 14 RSV-A genotypes and 24 RSV-B genotypes 
[45]. Several distinct RSV strains appear to cocirculate within an individual com-
munity during each annual epidemic with the predominant strain varying year 
to year [44, 46]. Multiple elements appear to determine prevailing annual strains 
including herd and maternal immunity, changes in social contacts and migration as 
well as viral factors [29, 47–49].
RSV’s capacity for genomic mutation is exemplified by the emergence of two 
novel genotypes, RSV-B BA and RSV-A ON1 genotypes. In 1999, the BA genotype 
was first detected in Buenos Aires, Argentina [50], and has since spread gradually 
and sequentially throughout the world [51], becoming the predominant group B gen-
otype, and even replacing all previous circulating RSV-B genotypes in some regions 
[52, 53]. Subsequently, the RSV-A genotype ON1 was identified in Ontario, Canada, 
in 2010 [54] and has rapidly spread worldwide [55]. Both genotypes demonstrate a 
60–72 base pair duplication in the G protein gene which may change the antigenic 
properties of the protein enabling evasion of the host immune response [50, 56].
The possibility that distinct RSV genotypes may have differing virulence has led to 
several studies in this area. Much interest has concerned the possible association of the 
ON1 genotype with less severe disease. Panayiotou et al. first described this association 
in 99 children <2 years of age hospitalised with a RSV respiratory tract infection over 
3 successive Cypriot winters [39]. The ON1 genotype was associated with significantly 
milder illness (as determined by a clinical severity score) than either GA1 (RSV-A) or 
BA (RSV-B) genotypes. This finding has also been observed in a number of subsequent 
studies including a recent study of 329 infants with a clinical diagnosis of bronchiolitis 
and infected with RSV alone [57, 58]. Infants with the NA1 genotype had a milder 
clinical course both in terms of clinical severity scores and need for admission to 
PICU. Conversely, other studies have reported a similar clinical course with different 
genotypes [36, 59] or that genotype ON1 was associated with more severe disease in a 
group of Vietnamese children hospitalised with signs of LRTI [60].
Once again, the lack of a consistent association between genotype and dis-
ease severity is presumably due to variable study design and geographic factors. 
However, other factors should be considered. All studies to date have encompassed 
multiple years to enable analysis of different viral strains as the dominant genotype 
varies year to year. This inherently introduces a significant confounder with changes 
between years in staff, clinical practice, herd immunity, etc. In addition, there is 
increasing evidence of virulence factors encoded in regions of the genome outside 
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the G protein hypervariable region that has been traditionally used for genotyping. 
Studies in the mouse model have demonstrated that specific sequences within the 
conserved central domain of the G protein influence RSV binding to the chemokine 
receptor CX3CR1 impacting host response [61] and sequences contained in the F 
protein are associated with significant differences in disease severity [62].
The possibility of different RSV genotypes having distinct infective properties 
is an attractive explanation for the diverse severity of RSV disease which merits 
further study. It is apparent that the interaction between RSV strain and disease is 
complex. Whole-genome sequencing perhaps provides the best future opportunity 
to further our understanding [1].
3. Host factors
3.1 Predisposing health factors
Pre-existing illness and disease have been long recognised as having a significant 
impact on the severity of RSV disease. RSV infection in children with congenital 
immunodeficiency (particularly of cell-mediated immunity) is associated with 
a more severe clinical course [63], and individuals requiring immunosuppres-
sive therapy (such as haemopoietic cell transplant (HCT) recipients and patients 
undergoing chemotherapy) also experience more sever disease. Following HCT, 
RSV infection is associated with significant morbidity, including complications 
such as late graft dysfunction and bronchiolitis obliterans syndrome. Mortality rates 
range from 7 to 83% depending on a number of risk factors including lymphopenia 
and high-dose total body irradiation [64–66]. Adult patients with leukaemia are 
particularly vulnerable to RSV infection with reported mortality rates between 20 
and 85% in those developing pneumonia [67] although children with leukaemia 
appear to follow a more benign clinical course [68].
Pre-existing cardiopulmonary disease has a significant impact on the clinical 
response to RSV infection. Underlying congenital heart disease in infants and 
children has long been recognised to be associated with more severe outcomes from 
RSV, including more frequent hospitalisation, longer lengths of stay and higher 
rates of intensive care unit admission [69]. Similarly, children with bronchopul-
monary disease have markedly increased morbidity and mortality due to RSV [70]. 
Adults with underlying cardiac and pulmonary diseases are also prone to severe 
respiratory illnesses with RSV infection [71]. Adults with chronic obstructive pul-
monary disease are particularly vulnerable to RSV infection with a high incidence 
of lower respiratory tract disease and frequent hospitalisation [71].
The impact of RSV at the extremes of age is significant. Premature birth is a 
significant risk factor for severe RSV disease; those born at less than 32 weeks of 
gestational age have approximately double the hospitalisation risk of infants born 
later [72]. Incomplete immunological and pulmonary maturation and reduced 
transfer of maternal antibodies are all thought to contribute to this increased risk. 
The burden in the elderly is also significant with evidence that the impact is similar 
to that of non-pandemic influenza, both in the community and in nursing homes 
[73]. RSV outbreaks in nursing homes have been well documented, studies report-
ing infection rates of over 10% with pneumonia in up to 55% of those affected 
and mortality rates of up to 20% [73]. A recent prospective, international study 
detected RSV in over 7% of moderate to severe acute respiratory episodes observed 
in elderly adults living at home and found that the incidence of RSV infection 
increased with age [13].
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3.2 Predisposing airway geometry
The potential impact of reduced premorbid lung function on the response to 
a subsequent RSV infection has been of interest for many years. Two initial stud-
ies published in 1995 demonstrated that a reduced maximum expiratory flow at 
functional residual capacity (VmaxFRC—believed to reflect the size of intrapulmo-
nary airways) measured in infancy before any lower respiratory tract illness was 
associated with subsequent virus-associated wheeze [74, 75]. Subsequently, a large 
prospective study of 2133 infants who had neonatal lung function performed found 
that those subsequently hospitalised with RSV infection had significantly decreased 
lung function compared to those with RSV infection managed in the community 
[76]. These data together would suggest that congenitally smaller airways may 
predispose infants to more severe RSV disease.
3.3 Host immune factors
The immune response to infection can be divided into two arms:
1. Innate immunity—this refers to nonspecific defence mechanisms that acti-
vate immediately or within hours of exposure to an infecting organism. The 
efficacy of these mechanisms does not rely on clonal expansion.
2. Adaptive immunity—the adaptive immune response relies on the clonal 
expansion of antigen-specific lymphocytes and can take several days to 
complete. A principal feature of the adaptive immune response is the genera-
tion of immunological memory enabling a more rapid and effective response 
to pathogens that have been previously encountered.
3.3.1 Innate immunity
The innate immune response to RSV infection consists of a coordinated response 
incorporating a variety of cell types and their products. The character of this 
response is a critical determinant of the outcome of infection. A slow, weak or 
inappropriate response will result in delayed viral clearance enabling the virus to 
spread to the lower airway producing enhanced pathology. An inappropriate innate 
response will also have a direct impact on the nature and efficacy of the adaptive 
immune response.
The importance of innate immunity is highlighted by genetic association studies 
which have identified the strongest associations with severe disease due to polymor-
phisms of the innate immune system at both the allele and genotype level [77, 78].
3.3.1.1 Toll-like receptors
Type I interferons (IFN-I, α/β) are an important part of the innate immune 
response to viral infection. Various cell intrinsic pattern recognition receptors 
(PRRs) including the Toll-like receptors (TLR) recognise RSV as foreign and 
potentially dangerous. This leads to the activation of key transcription factors 
including interferon regulatory factors which regulate the expression of IFN-I 
and pro-inflammatory cytokines [79]. IFN-I upregulates transcription of multiple 
interferon-stimulated genes (ISGs) via the IFN-I receptor, which interfere with viral 
replication, thus facilitating viral clearance.
TLR polymorphisms have been widely studied for their potential associa-
tion with severe RSV disease. Tal et al. identified an overrepresentation of a 
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heterozygous genotype in two TLR4 mutations (Asp299Gly and Thr399Ile) among 
a group of infants necessitating hospitalisation compared to a community-managed 
group [80]. Similarly, the same mutations were significantly associated with 
hospitalisation in a group of primarily premature infants with symptomatic RSV 
infection [81]. However, subsequent studies have failed to confirm these findings 
[82, 83] although one study has identified significant variability between different 
RSV epidemics in the genetic risk of severe disease associated with these polymor-
phisms [83]. This highlights the complex interplay between host genetic factors and 
the predominant circulating viral strain.
3.3.1.2 Surfactant proteins
The surfactant proteins (SPs) primarily reduce surface tension of the alveoli to 
prevent lung collapse but also make a significant contribution to innate immunity. 
In vitro, SP-A enhances uptake of RSV by macrophages, reduces RSV-induced 
suppression of host cell tumour necrosis factor-α (TNF-α) and augments the 
production of anti-inflammatory interleukin-10 (IL-10) [84]. SP-D-deficient mice 
develop severe disease on exposure to RSV and have delayed viral clearance [85]. 
Studies on ventilated infants with RSV infection have demonstrated low surfactant 
activity and reduced levels of SP-A, SP-B and SP-D compared to controls [86, 87]. In 
addition, genetic analyses have identified certain polymorphisms of the surfactant 
proteins that are associated with severe disease in RSV-infected infants [88, 89].
3.3.1.3 Inflammatory mediators
The initial contact between RSV and the host is typically at the nasal epithelium. 
The epithelial surfaces form a physical barrier that is impermeable to most infectious 
agents, acting as the first line of defence against invading organisms. In response to 
contact with RSV, the epithelium also releases a variety of pro-inflammatory media-
tors and cytokines that play an important part in the innate immune response. A 
number of in vitro studies have demonstrated the production of IL-1; IL-6; IL-8; 
tumour necrosis factor-α; regulated upon activation, normal T-cell expressed and 
presumably secreted (RANTES); and CXCL8 by RSV-infected primary airway 
epithelial cell cultures [90–92]. Macrophages and neutrophils are important phago-
cytes but also produce a wide range of immunological mediators, including MIP-1α, 
RANTES, IL-1, IL-6 and IL-8, when infected with RSV in vitro [93, 94]. Such 
mediators have a significant impact on both early inflammation as well as subsequent 
immunological responses. For example, IL-8 is chemotactic for neutrophils as well 
as being a potent activator. Similarly, MIP-1α and RANTES activate both monocytes 
and eosinophils as well as being potent CD4+ T-cell chemoattractants.
Respiratory secretions from infants and children infected with RSV have been 
found to contain many of these mediators [38, 95–97]. Some studies have also 
identified correlates between certain inflammatory mediator concentrations and 
disease severity. Higher levels of IL-8 have been identified in severe disease with a 
strong correlation with oxygen requirement and need for ventilation [96, 98]. Nasal 
concentrations of MIP-1α are significantly increased in children with RSV bron-
chiolitis that require oxygen therapy [99] and in RSV-infected adults that require 
hospitalisation [100].
There has been much interest in the contribution of RANTES, a potent 
chemoattractant for eosinophils, T cells and monocytes, to the pathogenesis of 
RSV disease. RANTES levels in tracheal aspirates have been found to correlate 
inversely with markers of disease severity in RSV bronchiolitis [95], and the 
ratio of TNF-receptor to RANTES in nasopharyngeal aspirates is significantly 
The Burden of Respiratory Syncytial Virus Infection in the Young
8
3.2 Predisposing airway geometry
The potential impact of reduced premorbid lung function on the response to 
a subsequent RSV infection has been of interest for many years. Two initial stud-
ies published in 1995 demonstrated that a reduced maximum expiratory flow at 
functional residual capacity (VmaxFRC—believed to reflect the size of intrapulmo-
nary airways) measured in infancy before any lower respiratory tract illness was 
associated with subsequent virus-associated wheeze [74, 75]. Subsequently, a large 
prospective study of 2133 infants who had neonatal lung function performed found 
that those subsequently hospitalised with RSV infection had significantly decreased 
lung function compared to those with RSV infection managed in the community 
[76]. These data together would suggest that congenitally smaller airways may 
predispose infants to more severe RSV disease.
3.3 Host immune factors
The immune response to infection can be divided into two arms:
1. Innate immunity—this refers to nonspecific defence mechanisms that acti-
vate immediately or within hours of exposure to an infecting organism. The 
efficacy of these mechanisms does not rely on clonal expansion.
2. Adaptive immunity—the adaptive immune response relies on the clonal 
expansion of antigen-specific lymphocytes and can take several days to 
complete. A principal feature of the adaptive immune response is the genera-
tion of immunological memory enabling a more rapid and effective response 
to pathogens that have been previously encountered.
3.3.1 Innate immunity
The innate immune response to RSV infection consists of a coordinated response 
incorporating a variety of cell types and their products. The character of this 
response is a critical determinant of the outcome of infection. A slow, weak or 
inappropriate response will result in delayed viral clearance enabling the virus to 
spread to the lower airway producing enhanced pathology. An inappropriate innate 
response will also have a direct impact on the nature and efficacy of the adaptive 
immune response.
The importance of innate immunity is highlighted by genetic association studies 
which have identified the strongest associations with severe disease due to polymor-
phisms of the innate immune system at both the allele and genotype level [77, 78].
3.3.1.1 Toll-like receptors
Type I interferons (IFN-I, α/β) are an important part of the innate immune 
response to viral infection. Various cell intrinsic pattern recognition receptors 
(PRRs) including the Toll-like receptors (TLR) recognise RSV as foreign and 
potentially dangerous. This leads to the activation of key transcription factors 
including interferon regulatory factors which regulate the expression of IFN-I 
and pro-inflammatory cytokines [79]. IFN-I upregulates transcription of multiple 
interferon-stimulated genes (ISGs) via the IFN-I receptor, which interfere with viral 
replication, thus facilitating viral clearance.
TLR polymorphisms have been widely studied for their potential associa-
tion with severe RSV disease. Tal et al. identified an overrepresentation of a 
9
Disease Severity in Respiratory Syncytial Virus Infection: Role of Viral and Host Factors
DOI: http://dx.doi.org/10.5772/intechopen.88782
heterozygous genotype in two TLR4 mutations (Asp299Gly and Thr399Ile) among 
a group of infants necessitating hospitalisation compared to a community-managed 
group [80]. Similarly, the same mutations were significantly associated with 
hospitalisation in a group of primarily premature infants with symptomatic RSV 
infection [81]. However, subsequent studies have failed to confirm these findings 
[82, 83] although one study has identified significant variability between different 
RSV epidemics in the genetic risk of severe disease associated with these polymor-
phisms [83]. This highlights the complex interplay between host genetic factors and 
the predominant circulating viral strain.
3.3.1.2 Surfactant proteins
The surfactant proteins (SPs) primarily reduce surface tension of the alveoli to 
prevent lung collapse but also make a significant contribution to innate immunity. 
In vitro, SP-A enhances uptake of RSV by macrophages, reduces RSV-induced 
suppression of host cell tumour necrosis factor-α (TNF-α) and augments the 
production of anti-inflammatory interleukin-10 (IL-10) [84]. SP-D-deficient mice 
develop severe disease on exposure to RSV and have delayed viral clearance [85]. 
Studies on ventilated infants with RSV infection have demonstrated low surfactant 
activity and reduced levels of SP-A, SP-B and SP-D compared to controls [86, 87]. In 
addition, genetic analyses have identified certain polymorphisms of the surfactant 
proteins that are associated with severe disease in RSV-infected infants [88, 89].
3.3.1.3 Inflammatory mediators
The initial contact between RSV and the host is typically at the nasal epithelium. 
The epithelial surfaces form a physical barrier that is impermeable to most infectious 
agents, acting as the first line of defence against invading organisms. In response to 
contact with RSV, the epithelium also releases a variety of pro-inflammatory media-
tors and cytokines that play an important part in the innate immune response. A 
number of in vitro studies have demonstrated the production of IL-1; IL-6; IL-8; 
tumour necrosis factor-α; regulated upon activation, normal T-cell expressed and 
presumably secreted (RANTES); and CXCL8 by RSV-infected primary airway 
epithelial cell cultures [90–92]. Macrophages and neutrophils are important phago-
cytes but also produce a wide range of immunological mediators, including MIP-1α, 
RANTES, IL-1, IL-6 and IL-8, when infected with RSV in vitro [93, 94]. Such 
mediators have a significant impact on both early inflammation as well as subsequent 
immunological responses. For example, IL-8 is chemotactic for neutrophils as well 
as being a potent activator. Similarly, MIP-1α and RANTES activate both monocytes 
and eosinophils as well as being potent CD4+ T-cell chemoattractants.
Respiratory secretions from infants and children infected with RSV have been 
found to contain many of these mediators [38, 95–97]. Some studies have also 
identified correlates between certain inflammatory mediator concentrations and 
disease severity. Higher levels of IL-8 have been identified in severe disease with a 
strong correlation with oxygen requirement and need for ventilation [96, 98]. Nasal 
concentrations of MIP-1α are significantly increased in children with RSV bron-
chiolitis that require oxygen therapy [99] and in RSV-infected adults that require 
hospitalisation [100].
There has been much interest in the contribution of RANTES, a potent 
chemoattractant for eosinophils, T cells and monocytes, to the pathogenesis of 
RSV disease. RANTES levels in tracheal aspirates have been found to correlate 
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raised in infants with severe RSV disease [101]. The potential protective impact 
of RANTES has been further explored through analysis of promoter and intronic 
polymorphisms in the RANTES gene. Certain polymorphisms (e.g., −403 G/A) 
have been associated with reduced disease severity and greater production of 
RANTES [102, 103].
3.3.1.4 Eosinophils
Eosinophils have been traditionally regarded as important in the innate immune 
response to helminthic infection although several studies have suggested their pos-
sible contribution to RSV immunity. Eosinophil cationic protein (ECP), a cytotoxic 
protein released with eosinophil activation, is found in nasal lavage fluid and serum 
from children with severe RSV infection [104]. ECP levels in nasopharyngeal secre-
tions have been found to correlate with disease severity [105, 106] suggesting a role 
for the eosinophil in the pathogenesis of RSV disease.
3.3.2 Adaptive immunity
3.3.2.1 Humoral immunity
The developing foetus acquires maternal IgG antibodies to RSV through the 
placenta actively. The transfer rate gradually increases from 30 weeks of gestation 
to a maximum between 38 and 40 weeks. Following birth, levels of neutralising 
antibody slowly diminish with a mean half-life of 26 days [107]. The quantity of 
antibody transferred is important in protecting infants against infection; higher 
specific antibody titres are associated with milder disease following RSV infection 
[108]. Infants also acquire antibodies from the mother through breast feeding with 
breast fed infants having significantly reduced oxygen requirement and length of 
stay following hospitalisation with RSV bronchiolitis [109].
There is considerable variability in the humoral response of infants to pri-
mary infection. During the first year of life, there is rapid maturation of the 
immune system, and this may account for much of this variability. In the first 
6 months of life, the serum IgA response is greater than that of IgG [110]. In 
older children, there is a predominant rise in IgG levels with IgG1 and IgG3 
subclasses accounting for the major part of this response [110], whereas IgG1 
and IgG2 subclasses form the bulk of the adult response [111]. As well as these 
qualitative differences in antibody response with age, there is also quantitative 
variation with generally very low titres of antibody produced in early infancy. 
The antibody titres against both the F and G surface proteins of RSV in infancy 
are 10 to 12 times lower than those observed in children over 12 months of age 
[112]. This blunted response appears to be caused by a combination of factors 
including the presence of residual maternal antibody and immaturity of the 
immune system [113].
Murine studies have demonstrated that the humoral response is an important 
factor in RSV disease severity. B-cell-depleted mice, which consequently have no 
antibody response to infection, experience greater illness on primary RSV infec-
tion [114]. Similarly, higher neutralising antibody titres in children are associated 
with a lower incidence of severe lower respiratory tract disease once infected 
with RSV. Clinical severity scores inversely correlate with antibody titres to the F 
protein in infants with RSV infection [115], and therapeutic trials of polyclonal 
and monoclonal antibodies have demonstrated reduced disease severity in treated 
infants [116, 117].
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3.3.2.2 Cell-mediated immunity
The cellular arm of the adaptive immune response is orchestrated primarily 
by cytotoxic T lymphocytes (CTLs) and T-helper (Th) lymphocytes. Cell-
mediated immunity is extremely important for the eradication and abrogation 
of the clinical response to RSV infection as highlighted by the severe impact of 
infection in individuals with severe congenital/acquired impairment of cellular 
immunity [63, 118].
3.3.2.2.1 Cytotoxic T lymphocytes (CD8+ T cells)
CTLs are pivotal for the control of many intracellular pathogens and have the 
capacity to differentiate into long-lived memory CTLs which provide a rapid, robust 
response to subsequent infection. CTLs have been found to have an important 
role in clearing RSV during animal studies. Mice that have been rendered athymic 
are unable to produce a CTL response to RSV infection and become chronically 
infected. Clearance of the virus can be subsequently achieved by injecting the mice 
with primed RSV-specific CTLs [119]. There is also some evidence that CTLs can 
contribute to severe disease if produced in large numbers [120].
Unfortunately, the role of CTLs in human RSV infection has been little studied 
largely due to the relatively modest RSV-specific T-cell responses observed in the 
blood and the low numbers of RSV-specific T-cell memory cells present between 
infections. Using HLA tetrameric staining, RSV-specific CD8+ T cells were analysed 
in bronchoalveolar lavage fluid and blood specimens from infants requiring ventila-
tory support for RSV bronchiolitis. RSV-specific T-cell numbers peaked in blood 
around days 9–12 (at the time of recovery), and there was no correlation between 
cell numbers and parameters of disease severity [121]. A similar pattern is observed 
in experimental infection of adult volunteers where antigen-specific CD8+ T-cell 
numbers peak 10 days after initial infection at approximately the same time as a 
fall in viral load and resolution of symptoms [122]. This would perhaps suggest an 
important contribution to viral clearance although the impact of CTLs on disease 
severity in man remains undefined.
3.3.2.2.2 T-helper lymphocytes (CD4+ T cells)
CD4+ T cells recognise antigens presented on MHC class II molecules, which are 
found on antigen-presenting cells. They respond by releasing cytokines which play a 
major role in instigating and shaping adaptive immune responses. The cytokines pro-
duced have been used to differentiate these cells into the two major classes of effector 
T cell—T helper (Th) 1 (producing type 1 cytokines) and Th2 (producing type 2 
cytokines) [123]. In general, type 1 cytokines (such as interferon-gamma (IFN-γ) 
and IL-12) favour the development of a strong cellular immune response and are an 
important component of an effective response to intracellular pathogens including 
viruses. Type 2 cytokines (such as IL-4 and IL-5) favour a strong humoral response to 
infection by promoting B-cell proliferation and increased production of antibodies. 
Type 2 cytokines also mediate allergic responses. Cross regulation occurs between the 
two responses, and responses deviated toward type 2 or away from type 1 are associ-
ated with more severe disease in several infectious disease model [124, 125].
Indirect evidence suggests that T-helper lymphocytes have a significant role in RSV 
disease with CD4+ T cells constituting the largest lymphocyte population in bron-
choalveolar lavage fluid obtained from infants ventilated for RSV bronchiolitis [126]. 
Subsequent studies have focussed on the exact nature of this CD4+ T-cell response.
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3.3.2.2 Cell-mediated immunity
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contribute to severe disease if produced in large numbers [120].
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blood and the low numbers of RSV-specific T-cell memory cells present between 
infections. Using HLA tetrameric staining, RSV-specific CD8+ T cells were analysed 
in bronchoalveolar lavage fluid and blood specimens from infants requiring ventila-
tory support for RSV bronchiolitis. RSV-specific T-cell numbers peaked in blood 
around days 9–12 (at the time of recovery), and there was no correlation between 
cell numbers and parameters of disease severity [121]. A similar pattern is observed 
in experimental infection of adult volunteers where antigen-specific CD8+ T-cell 
numbers peak 10 days after initial infection at approximately the same time as a 
fall in viral load and resolution of symptoms [122]. This would perhaps suggest an 
important contribution to viral clearance although the impact of CTLs on disease 
severity in man remains undefined.
3.3.2.2.2 T-helper lymphocytes (CD4+ T cells)
CD4+ T cells recognise antigens presented on MHC class II molecules, which are 
found on antigen-presenting cells. They respond by releasing cytokines which play a 
major role in instigating and shaping adaptive immune responses. The cytokines pro-
duced have been used to differentiate these cells into the two major classes of effector 
T cell—T helper (Th) 1 (producing type 1 cytokines) and Th2 (producing type 2 
cytokines) [123]. In general, type 1 cytokines (such as interferon-gamma (IFN-γ) 
and IL-12) favour the development of a strong cellular immune response and are an 
important component of an effective response to intracellular pathogens including 
viruses. Type 2 cytokines (such as IL-4 and IL-5) favour a strong humoral response to 
infection by promoting B-cell proliferation and increased production of antibodies. 
Type 2 cytokines also mediate allergic responses. Cross regulation occurs between the 
two responses, and responses deviated toward type 2 or away from type 1 are associ-
ated with more severe disease in several infectious disease model [124, 125].
Indirect evidence suggests that T-helper lymphocytes have a significant role in RSV 
disease with CD4+ T cells constituting the largest lymphocyte population in bron-
choalveolar lavage fluid obtained from infants ventilated for RSV bronchiolitis [126]. 
Subsequent studies have focussed on the exact nature of this CD4+ T-cell response.
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Murine studies have demonstrated that prior sensitisation to RSV surface 
proteins followed 3 weeks later by RSV infection can induce polarised cyto-
kine responses which follow broad type 1 and type 2 repertoires [127]. Type 2 
responses were associated with enhanced disease characterised by pulmonary 
haemorrhage and eosinophilia while those with type 1 responses had reduced 
immunopathology and enhanced viral clearance [128]. A type 2 cytokine response 
also correlates with quantitated pulmonary pathology following primary RSV 
infection of BALB/c mice [129].
Multiple human studies have examined type 1 and type 2 immune responses to 
RSV and have largely identified a similar predominance of type 2 cytokines in those 
with more severe disease. Type 1 cytokines (including IFN-γ and TNF-α) are increased 
in the circulation, the nose and lung during an RSV LRTI [96, 130, 131]. Lower IFN-γ 
levels are associated with increased severity scores, hypoxia and need for ventilation 
[97, 131–134]. Type 2 cytokines (including IL-4, IL-10 and IL-13) are also increased 
in the blood, nose and lung during RSV LRTI [95, 132, 135]. However, higher type 2 
cytokine levels are generally associated with more severe disease. Systemic IL-10 levels 
correlate with disease severity in RSV LRTI [136, 137] although respiratory tract IL-10 
levels would appear to be associated with milder disease features [95].
Multiple studies have also evaluated the type 1/type 2 immune balance through 
the quantification of cytokine ratio. The ratio of IL-4 to IFN-γ is raised both 
systemically and in the respiratory tract in patients with bronchiolitis that require 
oxygen therapy suggesting a skew towards type 2 responses [138, 139]. Similarly, 
IL-4:IFN-γ and IL-10:IL-12 ratios are raised in nasal lavage obtained from infants 
with RSV who develop bronchiolitis compared to those that develop signs of an 
URTI only [23], and type 2 cytokines predominate in nasopharyngeal specimens 
from children with hypoxic RSV LRTI [96].
Overall, current evidence would support a bias towards a type 2 T-helper cell 
response in severe RSV infection. Further studies are, however, required to confirm 
these findings and would ideally analyse prospectively the cytokine response both 
systemically and within the airway. Such studies should, also, examine both chil-
dren and adults with RSV infection using relevant study groups (URTI, LRTI) and 
strictly control for potential confounding factors such as sampling times (relative to 
infection onset) and age differences between groups.
3.3.2.2.3 Regulatory T cells
Regulatory T cells (Tregs) are immunoregulating cells that maintain the immu-
nological equilibrium by controlling effector T-cell activation and hence preventing 
tissue damage during the immune response to infections [140]. Animal studies 
in Treg-depleted mice have highlighted their importance. RSV infection of Treg-
depleted mice results in severe disease with a significantly elevated viral load and an 
exuberant cytotoxic T-cell response highlighting the importance of Tregs for both 
viral clearance and control of the RSV-specific T-cell response [141]. A recent study 
of infants with severe bronchiolitis demonstrated a prolonged reduction in Tregs 
in these patients compared to a similarly aged, healthy control group [142]. While 
intriguing, further studies are required to confirm this finding and to clarify the 
role of Tregs in severity of RSV disease.
4. Conclusion
The broad spectrum of disease due to RSV infection likely represents a complex 
interplay between multiple viral and host factors. Despite significant research in 
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this area, our understanding of the relative importance of each factor is limited 
although recent studies that have examined multiple components of the virus-host 
interaction have provided some insight. Individual viral strains have differing 
infective properties which primarily determine RSV virulence alongside other fac-
tors such as viral load. The host immune response is increasingly recognised as an 
important determinant of disease severity. Other host factors including underlying 
immunological/cardiopulmonary disease and small airway geometry in infancy also 
appear to have an important impact.
Each year 2–3% of all infants require hospitalisation due to RSV outbreaks [6]. 
These epidemics result in substantial healthcare costs with direct medical costs for 
children <5 years old amounting to over $600 million in the United States alone 
[143]. Despite the substantial impact of RSV, advances in effective prevention and 
treatment have been slow. Future studies that consider fully the contribution of 
both viral and host factors in the pathogenesis of severe disease will undoubtedly 
facilitate the development of effective therapies.
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Resolving the Debate on RSV 
Prophylaxis in Late Preterm 
Infants
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Abstract
There is still active debate in the scientific literature about the importance of 
providing respiratory syncytial virus (RSV) prophylaxis to late preterm infants 
born at 33–35 weeks’ gestational age (wGA). The American Academy of Pediatrics 
and the Canadian Paediatric Society position statements only advocate for RSV 
prophylaxis for infants <30 wGA. Several publications prove the contrary, report-
ing substantial morbidity and even mortality in older GA infants, following RSV 
infection. Consequently, other Societies, such as from Spain and Italy, have differ-
ent criteria, and include as candidates 30–32 wGA infants and 33–35 wGA infants 
with risk factors for severe RSV disease. This chapter will systematically examine 
the current evidence for RSV prophylaxis in both early and late preterm infants 
29–35 wGA and the cost-effectiveness of this strategy with the use of risk scoring 
tools. The authors will attempt to reconcile the misconception that late preterm 
infants do not merit RSV prophylaxis and hopefully resolve the long-standing 
debate that currently exists in many countries worldwide.
Keywords: respiratory syncytial virus, palivizumab, prematurity, cost effectiveness, 
prevention, risk scoring tools
1. Introduction
Respiratory syncytial virus (RSV) infection is a common cause of lower respira-
tory tract infection (LRTI) in young children and is associated with a high global 
burden of incurred illness. In 2015, 2.8 million new episodes of RSV-related infec-
tions were reported in children <5 years of age in high income countries [1]. Of 
these, at least 383,000 cases required hospital admissions with 3300 accompanying 
deaths [1]. These figures represent a major healthcare burden, with costs estimated 
to be $545 million in the United States alone in 2009 [2].
Preterm birth, those born <37 weeks’ gestational age (wGA), has been associ-
ated with an increased risk for severe RSV-related disease requiring hospitalization 
(RSVH) [3]. Possible explanations for the increased RSV infection rates in preterm 
infants are incomplete airway development with reduced alveolar and bronchiolar 
diameter, increased air space wall thickness, immature immunologic responses, 
and reduced levels of maternally transmitted, RSV-specific antibodies compared to 
infants born at term [4]. Globally, about 15 million infants per year are estimated to 
be born premature, nearly 10% of all births, and thus are at potentially increased 
risk for RSV infection [5, 6]. Furthermore, the World Health Organization (WHO) 
29
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Abstract
There is still active debate in the scientific literature about the importance of 
providing respiratory syncytial virus (RSV) prophylaxis to late preterm infants 
born at 33–35 weeks’ gestational age (wGA). The American Academy of Pediatrics 
and the Canadian Paediatric Society position statements only advocate for RSV 
prophylaxis for infants <30 wGA. Several publications prove the contrary, report-
ing substantial morbidity and even mortality in older GA infants, following RSV 
infection. Consequently, other Societies, such as from Spain and Italy, have differ-
ent criteria, and include as candidates 30–32 wGA infants and 33–35 wGA infants 
with risk factors for severe RSV disease. This chapter will systematically examine 
the current evidence for RSV prophylaxis in both early and late preterm infants 
29–35 wGA and the cost-effectiveness of this strategy with the use of risk scoring 
tools. The authors will attempt to reconcile the misconception that late preterm 
infants do not merit RSV prophylaxis and hopefully resolve the long-standing 
debate that currently exists in many countries worldwide.
Keywords: respiratory syncytial virus, palivizumab, prematurity, cost effectiveness, 
prevention, risk scoring tools
1. Introduction
Respiratory syncytial virus (RSV) infection is a common cause of lower respira-
tory tract infection (LRTI) in young children and is associated with a high global 
burden of incurred illness. In 2015, 2.8 million new episodes of RSV-related infec-
tions were reported in children <5 years of age in high income countries [1]. Of 
these, at least 383,000 cases required hospital admissions with 3300 accompanying 
deaths [1]. These figures represent a major healthcare burden, with costs estimated 
to be $545 million in the United States alone in 2009 [2].
Preterm birth, those born <37 weeks’ gestational age (wGA), has been associ-
ated with an increased risk for severe RSV-related disease requiring hospitalization 
(RSVH) [3]. Possible explanations for the increased RSV infection rates in preterm 
infants are incomplete airway development with reduced alveolar and bronchiolar 
diameter, increased air space wall thickness, immature immunologic responses, 
and reduced levels of maternally transmitted, RSV-specific antibodies compared to 
infants born at term [4]. Globally, about 15 million infants per year are estimated to 
be born premature, nearly 10% of all births, and thus are at potentially increased 
risk for RSV infection [5, 6]. Furthermore, the World Health Organization (WHO) 
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reported that the incidence of premature birth is rising [5]. This highlights the 
importance of preventing RSV-related LRTI and indeed, the WHO has declared the 
prevention of RSV to be a key healthcare priority [7]. Although several vaccines 
and antibodies are currently in preclinical or clinical development, it is likely to be 
several more years before any become commercially available [8, 9]. Therefore, cur-
rent therapeutic prevention relies solely on palivizumab, a humanized monoclonal 
antibody, which is indicated for the prevention of RSVH in high-risk infants, such 
as preterm infants born at ≤35 wGA or those with bronchopulmonary dysplasia 
(BPD)/chronic lung disease (CLD) or congenital heart disease (CHD) [10, 11]. 
However, several current guidelines, most notably from the American Academy 
of Pediatrics (AAP) and the Canadian Pediatric Society, seek to rationalize its use 
by recommending palivizumab only for infants born at <29 wGA without CLD 
[12–15], leaving the majority of preterm infants without therapeutic protection.
Risk-scoring tools (RSTs), models to estimate the risk of RSVH based on pre-
determined risk factors, have been developed to help identify infants at highest risk 
for RSVH, which may allow for targeted and cost-effective prophylaxis of infants 
born late preterm [16–19]. Some guidelines, such as those from Spain [20], Italy [21] 
and Austria [22], advocate the use of such a risk factor-based approach to extend 
prophylaxis to those preterm infants ≥30 wGA at highest risk.
This chapter aims to provide a rationale for palivizumab prophylaxis in late pre-
term infants and show that this can be cost effective with the use of validated RSTs.
2. Literature search
A literature review was undertaken using PubMed, EMBASE, and the Cochrane 
Library of studies including <37 wGA infants without CLD or CHD but with 
confirmed or probable RSV infection, published between 01 January 1998 and 31 
December 2018. To maximize comparability of data, only studies conducted in 
Western countries, defined as the US, Canada, and Europe (including Turkey and 
the Russian Federation) were included. The following search terms were used, com-
bined with Medical Subject Headings (MeSH): [“RSV” OR “respiratory syncytial 
virus” OR “lower respiratory tract infection” OR “LRTI” OR “acute respiratory tract 
infection” OR “ARTI” OR “ARI” OR “lower respiratory infection (LRI)” OR “bron-
chiolitis”] AND [“preterm” OR “premature” OR “gestational age” OR “gestation”] 
AND [“hospitalization*] OR [predisposition” OR “risk factor”] OR [“palivizumab” 
OR “Synagis” OR “immunoprophylax*” OR “prophylax*”] OR [“cost effective*” OR 
“Cost”] AND limits: “human, child (birth to 18 years)”. Additional publications and 
reference citations of potential relevance were included as identified by the authors. 
All original studies, systematic reviews, meta-analyses, and prophylaxis guidelines 
with at least an English abstract were reviewed.
As this chapter was based solely on published data, ethical approval was  
not required.
3. Results and discussion
3.1 Literature search
A total of 3532 publications were identified from the literature search, of which 
136 were deemed relevant (Figure 1). Another 20 references were identified from 
other sources, resulting in a final number of 156 publications considered during the 
drafting of this chapter.
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3.2 What do current guidelines recommend?
There is considerable variation in the published recommendations from national 
guidelines on the use of palivizumab prophylaxis in preterm infants. The AAP 2014 
policy [13, 14], which was unchanged following a review of new evidence in 2017 
[15], recommends prophylaxis for healthy preterm infants only if born ≤29 weeks 
and 0 days (29o wGA) and aged <1 year at the start of the RSV season. The justifica-
tion for this recommendation was partly based on a prospective, population-based 
surveillance program (n = 2149), undertaken from 2000 to 2005 in the US, which 
concluded that RSVH rates did not significantly differ between term (≥37 wGA) 
and preterm (<37 wGA) infants (5.3 vs. 4.6 per 1000 infants, respectively) [23]. 
Infants born at <30 wGA, on the other hand, experienced a significantly higher 
RSVH rate of 18.7 per 1000 infants [23]. Further evidence cited was from an 
analysis of the Tennessee Medicaid database (n = 248,652 infant-years), conducted 
in the 1990s, which reported higher rates of RSVH in infants <29 wGA compared to 
term infants with no underlying medical condition [24]. This difference remained 
consistently higher at up to 23 months of age: 0–5 months, 93.8 vs. 44.1 per 1000 
infants; 6–11 months, 46.1 vs. 15.0 per 1000 infants; and, 12–23 months, 30.0 vs. 
3.7 per 1000 infants [24]. Another study, which included 1029 ≤ 32 wGA preterm 
infants, found a decreasing RSVH incidence with increasing GA: ≤26 wGA, 139 per 
1000 infants; 27–28 wGA, 99 per 1000 infants; 29–30 wGA, 75 per 1000 infants; 
and 30–32 wGA, 44 per 1000 infants [25]. Predicated on this evidence, the AAP 
concluded that the risk of RSVH is considerably higher in those born ≤29° wGA 
compared to those born between 291 and 356 wGA and, therefore, prophylaxis 
should be recommended only in the former [13, 14]. A similar recommendation and 
rationale is presented in the Canadian RSV position statement, published in 2015 
[12]. The Canadian guideline concludes that it is “reasonable but not essential” to 
offer prophylaxis to infants born <30 wGA who are younger than 6 months at the 
start of the RSV season, but those born later do not merit prophylaxis, as the magni-
tude of difference in RSVH incidence between moderate to late preterm infants and 
infants born at term is not great enough to justify prophylaxis in this group [12]. The 
authors add that preterm infants are also less vulnerable to RSV infection nowadays 
Figure 1. 
PRISMA diagram: RSVH in preterm infants (<37 wGA) who received palivizumab.
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due to advances in technology and increased awareness of infection transmission. 
Preterm infants born >30 wGA are only eligible for prophylaxis if they live in 
remote regions and would require air transportation for hospitalization [12].
Other guidelines recommend more liberal use of prophylaxis for preterms, with 
Israeli guidelines, for example, recommending palivizumab for all preterm infants 
<33 wGA who are aged ≤1 year at the start of the RSV season and 33–35 wGA who 
are ≤6 months [26]. The Spanish and Italian guidelines recommend prophylaxis for 
those born between 29 and 31 wGA and aged ≤6 months at the start of the RSV sea-
son or if discharged during the season [20, 21]. For 32–35 wGA infants ≤6 months 
at the start of the RSV season, risk factors predisposing to severe infection and/or 
need for hospitalization guide the use of prophylaxis [20, 21]. Similar recommenda-
tions are reported in a recently published international, expert consensus guideline 
that guides cost-effective use of prophylaxis for high-risk 32–35 wGA infants with 
a validated RST [27]. Austrian guidelines have also adopted risk factors to guide 
prophylaxis for all 29–35 wGA infants, but with a chronological age cut-off of 
<6 months for 29–32 wGA and <3 months for 33–35 wGA [22].
3.3 Are late preterm infants at increased risk of RSVH compared to term infants?
Many studies in the literature report higher RSVH rates in late preterm infants 
and children (32–36 wGA) compared to those born at term (Table 1) [23, 28–31]. In 
a Dutch, community-based, cohort study that included 2099 children born between 
2002 and 2003 (62 with RSVH), otherwise healthy 32–36 wGA children had a three-
fold higher RSVH rate compared with full term children (3.9 vs. 1.2%, respectively; 
relative rate 3.2) [28]. Further evidence comes from a US, retrospective, cohort 
study involving 599,535 children (7597 admitted for RSVH) that reported a higher 
RSVH incidence in 33–36 wGA children compared to full term children (12.1 vs. 
7.8 per 1000 person-years) [29]. The adjusted hazard ratio for RSVH was 2.45 and 
1.92 for children born at 33–34 wGA and 34–36 wGA, respectively [29]. Another US 
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study, which included 247,566 infants (5322 RSVHs), found that 32–34 wGA infants 
were at double the risk of RSVH compared to term infants of the same age (odds 
ratio [OR] 1.94–2.41), and that the risk was highest in the youngest infants [32]. 
Young age was also associated with an increased risk of RSVH in 32–35 wGA infants 
in the REPORT study (n = 1642) [33]. Interestingly, older age was associated with 
higher rates of outpatient RSV visits, perhaps related to disease exposure [33]. A 
Danish database analysis found that, while RSVH incidence decreased with increas-
ing GA, 33–35 wGA children still had a RSVH rate twice as high as full term children 
(28.0 vs. 14.1 per 1000 years at risk) [30]. Another retrospective study, from Spain, 
investigating infants born between 1996 and 2000 (n = 357), reported a RSVH 
rate of 44.2 per 1000 children for <33 wGA infants compared to 1.91 per 1000 for 
≥38 wGA infants [31]. In this study, 33–35 wGA infants had the highest RSVH rate 
at 78.1 per 1000 [31].
Other studies have reported that there is not necessarily a simple linear rela-
tionship between lower GA and increased risk of RSVH. For example, in a large 
American database analysis involving 3,347,020 infants, RSVH rates were similar 
across all gestational age groups from <29 to 36 wGA (Figure 2) [34]. In 2016, a 
systematic review summarizing the evidence from 85 studies undertaken between 
1995 and 2015 concluded that, due to considerable variability in methodologies 
and results, it could not be clearly determined that infants born at younger GAs 
had higher RSVH rates [3]. Overall, reported RSVH rates were approximately three 
times higher in premature than term infants, although there was considerable vari-
ability across studies (range 1.1–8.1 times higher) [3].
Of potential note, two of the key studies cited by the AAP as evidence to restrict 
prophylaxis to ≤29° wGA infants reported moderate to late preterm infants to be 
at high risk of RSVH when considering those aged <6 months [23, 24]. In the US 
population-based surveillance program [23], the RSVH rate for 32–34 wGA infants 
≤5 months of age was 11.0 per 1000 children, compared to a rate of 2.6 per 1000 for 
those aged 6–23 months. Perhaps more revealing, the Tennessee Medicaid data-
base analysis [24] reported a RSVH rate of 79.8 per 1000 children for 33–35 wGA 
infants <6 months old compared to 44.1 per 1000 for age-matched, low-risk infants 
(incidence rate ratio: 1.8, 95% confidence interval [CI]: 1.5–2.1).
Figure 2. 
Rates of RSVH by gestational age group [34]. Hospitalization rates of infants aged less than 1 year at the time 
of first RSVH in a large American database analysis involving 1,683,188 infants insured via Medicaid and 
1,663,832 commercially insured infants [34]. RSVH, respiratory syncytial virus-related hospitalization; wGA, 
weeks’ gestational age.
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study, which included 247,566 infants (5322 RSVHs), found that 32–34 wGA infants 
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Young age was also associated with an increased risk of RSVH in 32–35 wGA infants 
in the REPORT study (n = 1642) [33]. Interestingly, older age was associated with 
higher rates of outpatient RSV visits, perhaps related to disease exposure [33]. A 
Danish database analysis found that, while RSVH incidence decreased with increas-
ing GA, 33–35 wGA children still had a RSVH rate twice as high as full term children 
(28.0 vs. 14.1 per 1000 years at risk) [30]. Another retrospective study, from Spain, 
investigating infants born between 1996 and 2000 (n = 357), reported a RSVH 
rate of 44.2 per 1000 children for <33 wGA infants compared to 1.91 per 1000 for 
≥38 wGA infants [31]. In this study, 33–35 wGA infants had the highest RSVH rate 
at 78.1 per 1000 [31].
Other studies have reported that there is not necessarily a simple linear rela-
tionship between lower GA and increased risk of RSVH. For example, in a large 
American database analysis involving 3,347,020 infants, RSVH rates were similar 
across all gestational age groups from <29 to 36 wGA (Figure 2) [34]. In 2016, a 
systematic review summarizing the evidence from 85 studies undertaken between 
1995 and 2015 concluded that, due to considerable variability in methodologies 
and results, it could not be clearly determined that infants born at younger GAs 
had higher RSVH rates [3]. Overall, reported RSVH rates were approximately three 
times higher in premature than term infants, although there was considerable vari-
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infants <6 months old compared to 44.1 per 1000 for age-matched, low-risk infants 
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3.4 What are the consequences of RSVH in late preterm infants?
The health burden associated with RSVH in late preterm infants has been 
shown to be substantial [28, 35–38]. A pooled analysis of 7 prospective studies 
from across the Northern Hemisphere, involving 7820 infants born 33–35 wGA 
[39–45], reported a median length of stay (LOS) in hospital for RSV of 5.7 days, 
with 22.2% of infants requiring intensive care unit (ICU) admission for a 
median of 8.3 days [35]. Supplemental oxygen support was required by 70.4% 
of cases for a median of 4.9 days and 12.7% required mechanical ventilation for 
a median of 4.8 days [35]. The US SENTINEL1 study (n = 709) reported a mean 
RSVH LOS of 5 days with 42% of 29–35 wGA infants being admitted to the 
ICU (mean ICU LOS: 6 days) [36]. Of those admitted to the ICU, 19% required 
mechanical ventilation [46]. In a Dutch cohort study [28], the RSV disease bur-
den was found to be similar between <32, 32–36 and 38–42 wGA infants, with 
no significant differences in terms of hospital LOS (median of 8 vs. 7 vs. 7 days, 
respectively; p > 0.3), oxygen use (82.4 vs. 60.5 vs. 85.7%; p > 0.1), mechanical 
ventilation (5.9 vs. 15.8 vs. 42.9%; p > 0.1), or gavage feeding (29.4 vs. 39.5 vs. 
42.9%; p > 0.6). Other studies, however, have indicated that the disease burden 
in late preterm infants is higher than in term infants [37, 38]. In a European 
survey of 3474 infants hospitalized with LRTI [37], while overall LOS in hospital 
was similar for 33–36 wGA and term infants (mean 11 vs. 9 days, respectively), 
33.8% of the former were admitted to the ICU compared to only 14.1% of the 
latter. The highest disease burden was found in <29 wGA infants (mean LOS 
29 days; 54.3% ICU) followed by 29–32 wGA infants (mean 24 days; 48.8% ICU) 
[37]. A retrospective US study [38], involving 215 term infants and 89 infants 
<37 wGA, reported that 33–35 wGA infants had the highest rate of intubation 
(38.7 vs. ≤32 wGA: 21.4% vs. 36 wGA: 20.0 vs. ≥37 wGA: 12.1%; p = 0.002) and 
longest hospital LOS (mean 8.4 vs. 6.8 vs. 4.9 vs. 4.1 days; p < 0.0001) and ICU 
LOS (mean 7.7 vs. 5.8 vs. 4.2 vs. 3.8 days; p = 0.021) compared with infants in 
other GA groups.
As a consequence of RSVH, preterm infants may develop longer-term morbidi-
ties, such as recurrent wheezing [47–51]. In the SPRING study, a multicenter, 
observational, nested, case–control study undertaken in Spain, 32–35 wGA infants 
with RSVH (n = 125) had a significantly higher incidence of recurrent wheez-
ing through the first 6 years of life, independent of familial or childhood atopy, 
compared to infants born at the same GA without RSVH (n = 362) (66.7 vs. 49.2%, 
respectively; p = 0.001) [47]. While current wheezing rates remained higher 
in cases than controls each year, the difference remained significant only until 
3 years old. Allied to this, respiratory-related quality of life was significantly lower 
in RSVH cases than controls (TAPQOL: 93.96 vs. 95.76, respectively; p = 0.001). 
Hospital resource use through 6 years of life was also higher in RSVH cases than 
controls (outpatient services: 84.0 vs. 66.3%, respectively, p < 0.001; emergency 
care: 62.4 vs. 33.7%, p < 0.001). Further analysis revealed that RSVH was the single 
most important factor for recurrent wheezing (OR: 4.40; p < 0.001) [47]. Similar 
results have been reported in the Dutch RISK study [51]. At the 6-year follow-up of 
this birth cohort of 2210 32–35 wGA infants, the current wheezing rate was 27.7% 
for RSVH cases and 17.6% for non-hospitalized infants (OR: 1.8; 95% CI: 1.11–2.85). 
RSVH was found to be an independent risk factor for current wheezing at 6 years 
in children without atopic predisposition (OR: 4.1; 95% CI: 1.22–12.52) [51]. Other 
studies have reported higher healthcare resource utilization (including emergency 
department visits, outpatient visits, and hospitalizations) in late preterm infants 
in the year following RSV LRTI compared to their counterparts without such an 
infection [52, 53].
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3.5 How effective is palivizumab prophylaxis in late preterm infants?
Palivizumab has proven effective in late preterm infants, reducing the incidence 
of RSVH by up to 82% in prospective, comparative studies (Table 2) [8, 10, 11, 
39, 54]. A post-hoc analysis of the pivotal IMpact study, a randomized clinical trial 
including 724 preterm infants, showed the effectiveness of palivizumab to be 
similar in <29 wGA and 32–35 wGA infants (relative risk reduction: 80.4 vs. 82.1%, 
respectively) [11]. The Spanish FLIP-2 study, which reported a 68.3% reduction in 
RSVH with prophylaxis, found that not receiving palivizumab was an independent 
risk factor for RSVH (OR: 0.25; 95% CI: 0.13–0.49) in 32–35 wGA infants [39]. 
Registry data have confirmed the efficacy of palivizumab, with the Palivizumab 
Outcomes Registry from the US reporting RSVH rates of 0.2–1.6% in 32–35 wGA 
infants across four RSV seasons (2000–2004) [55], compared to 10.1% in the pla-
cebo arm of the IMpact trial [11]. Similar results were seen in the Canadian Registry 
of Palivizumab (CARESS) [56], with a RSVH incidence of 1.4% in 33–35 wGA 
infants during the 2006–2011 RSV seasons, compared to 8.2% (untreated subjects) 
in the IMpact study [11]. A propensity score weighted regression analysis based on 
a prospective, international trial (n = 849), showed that palivizumab prophylaxis 
significantly reduced RSVHs by 74.1% in 29–35 wGA infants, without comorbidi-
ties, aged ≤6 months [57].
Some studies have indicated that restricting palivizumab to ≤29 wGA infants 
does not increase the overall RSVH rate in children <2 years, while saving money on 
palivizumab prescriptions [58, 59]. A retrospective US study reported no differ-
ence in RSVH rates following introduction of the AAP 2014 policy (pre: 5.37/1000 
vs. post: 5.78/1000; p = 0.622) [58]. Similar results were reported in Italy follow-
ing introduction of the same policy in 2016, with the RSVH rate being 6.3/1000 
before implementation and 5.5/1000 afterwards [59]. Other studies, however, have 
reported RSVH rates to have increased by up to 103% following implementation of 
a more restrictive policy [60–63].
Several studies have indicated that, by preventing RSV infection, palivizumab 
can reduce subsequent wheezing in premature children, including those born late 
preterm [48, 54, 64–66]. In the MAKI study, a randomized, placebo-controlled trial 
of palivizumab that included 429 infants born at 32–35 wGA, the proportion of 
children with wheezing was reduced by 41.9% in the palivizumab group at 6 years 
(11.6 vs. 19.9% for placebo) [48]. Similar results were seen in the Japanese CREW 
study (n = 444; 349 received palivizumab ≤1 year), where recurrent wheezing was 
significantly lower in palivizumab-treated, 33–35 wGA infants than chronologically 
age-matched untreated infants (15.3 vs. 31.6%, respectively; p = 0.003) [65].
Study Number Gestational 
age group
RSVH incidence RRR 
(%)
Palivizumab Untreated
Notario 2014 [11] 724 32–35 wGA 1.8% 10.1% 82.1%
33–35 wGA 2.2% 8.2% 73.2%
MAKI study, Blanken 2013 [54] 429 33–35 wGA 0.9% 5.1% 82.4%
FLIP-2 study, Figueras-Aloy 2008 
[39]
5441 32–35 wGA 1.3% 4.1% 68.3%
RRR: relative risk reduction; RSVH: Respiratory-syncytial-virus-related hospitalization; wGA: weeks’ gestational age.
Table 2. 
Prospective, comparative studies on the effectiveness of palivizumab prophylaxis in reducing RSVH in late 
preterm infants.
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3.4 What are the consequences of RSVH in late preterm infants?
The health burden associated with RSVH in late preterm infants has been 
shown to be substantial [28, 35–38]. A pooled analysis of 7 prospective studies 
from across the Northern Hemisphere, involving 7820 infants born 33–35 wGA 
[39–45], reported a median length of stay (LOS) in hospital for RSV of 5.7 days, 
with 22.2% of infants requiring intensive care unit (ICU) admission for a 
median of 8.3 days [35]. Supplemental oxygen support was required by 70.4% 
of cases for a median of 4.9 days and 12.7% required mechanical ventilation for 
a median of 4.8 days [35]. The US SENTINEL1 study (n = 709) reported a mean 
RSVH LOS of 5 days with 42% of 29–35 wGA infants being admitted to the 
ICU (mean ICU LOS: 6 days) [36]. Of those admitted to the ICU, 19% required 
mechanical ventilation [46]. In a Dutch cohort study [28], the RSV disease bur-
den was found to be similar between <32, 32–36 and 38–42 wGA infants, with 
no significant differences in terms of hospital LOS (median of 8 vs. 7 vs. 7 days, 
respectively; p > 0.3), oxygen use (82.4 vs. 60.5 vs. 85.7%; p > 0.1), mechanical 
ventilation (5.9 vs. 15.8 vs. 42.9%; p > 0.1), or gavage feeding (29.4 vs. 39.5 vs. 
42.9%; p > 0.6). Other studies, however, have indicated that the disease burden 
in late preterm infants is higher than in term infants [37, 38]. In a European 
survey of 3474 infants hospitalized with LRTI [37], while overall LOS in hospital 
was similar for 33–36 wGA and term infants (mean 11 vs. 9 days, respectively), 
33.8% of the former were admitted to the ICU compared to only 14.1% of the 
latter. The highest disease burden was found in <29 wGA infants (mean LOS 
29 days; 54.3% ICU) followed by 29–32 wGA infants (mean 24 days; 48.8% ICU) 
[37]. A retrospective US study [38], involving 215 term infants and 89 infants 
<37 wGA, reported that 33–35 wGA infants had the highest rate of intubation 
(38.7 vs. ≤32 wGA: 21.4% vs. 36 wGA: 20.0 vs. ≥37 wGA: 12.1%; p = 0.002) and 
longest hospital LOS (mean 8.4 vs. 6.8 vs. 4.9 vs. 4.1 days; p < 0.0001) and ICU 
LOS (mean 7.7 vs. 5.8 vs. 4.2 vs. 3.8 days; p = 0.021) compared with infants in 
other GA groups.
As a consequence of RSVH, preterm infants may develop longer-term morbidi-
ties, such as recurrent wheezing [47–51]. In the SPRING study, a multicenter, 
observational, nested, case–control study undertaken in Spain, 32–35 wGA infants 
with RSVH (n = 125) had a significantly higher incidence of recurrent wheez-
ing through the first 6 years of life, independent of familial or childhood atopy, 
compared to infants born at the same GA without RSVH (n = 362) (66.7 vs. 49.2%, 
respectively; p = 0.001) [47]. While current wheezing rates remained higher 
in cases than controls each year, the difference remained significant only until 
3 years old. Allied to this, respiratory-related quality of life was significantly lower 
in RSVH cases than controls (TAPQOL: 93.96 vs. 95.76, respectively; p = 0.001). 
Hospital resource use through 6 years of life was also higher in RSVH cases than 
controls (outpatient services: 84.0 vs. 66.3%, respectively, p < 0.001; emergency 
care: 62.4 vs. 33.7%, p < 0.001). Further analysis revealed that RSVH was the single 
most important factor for recurrent wheezing (OR: 4.40; p < 0.001) [47]. Similar 
results have been reported in the Dutch RISK study [51]. At the 6-year follow-up of 
this birth cohort of 2210 32–35 wGA infants, the current wheezing rate was 27.7% 
for RSVH cases and 17.6% for non-hospitalized infants (OR: 1.8; 95% CI: 1.11–2.85). 
RSVH was found to be an independent risk factor for current wheezing at 6 years 
in children without atopic predisposition (OR: 4.1; 95% CI: 1.22–12.52) [51]. Other 
studies have reported higher healthcare resource utilization (including emergency 
department visits, outpatient visits, and hospitalizations) in late preterm infants 
in the year following RSV LRTI compared to their counterparts without such an 
infection [52, 53].
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vs. post: 5.78/1000; p = 0.622) [58]. Similar results were reported in Italy follow-
ing introduction of the same policy in 2016, with the RSVH rate being 6.3/1000 
before implementation and 5.5/1000 afterwards [59]. Other studies, however, have 
reported RSVH rates to have increased by up to 103% following implementation of 
a more restrictive policy [60–63].
Several studies have indicated that, by preventing RSV infection, palivizumab 
can reduce subsequent wheezing in premature children, including those born late 
preterm [48, 54, 64–66]. In the MAKI study, a randomized, placebo-controlled trial 
of palivizumab that included 429 infants born at 32–35 wGA, the proportion of 
children with wheezing was reduced by 41.9% in the palivizumab group at 6 years 
(11.6 vs. 19.9% for placebo) [48]. Similar results were seen in the Japanese CREW 
study (n = 444; 349 received palivizumab ≤1 year), where recurrent wheezing was 
significantly lower in palivizumab-treated, 33–35 wGA infants than chronologically 
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3.6 Can the use of risk factors target infants at highest risk for RSV infection and 
improve the cost-effectiveness of prophylaxis in the late preterm population?
A key argument for restricting the use of palivizumab to <29 wGA infants is 
cost-effectiveness. Late preterm infants represent approximately 85% of preterm 
births [6], and it is unrealistic that prophylaxis of all these infants would ever be 
cost-effective. For this reason, the use of risk factors, to identify infants at the 
highest risk of RSVH, appears a pragmatic approach. There have been several 
RSTs developed and validated, including those in Canada [17], Spain [18], and the 
Netherlands [41]. Recently, a RST, involving 32–35 wGA infants, was published 
using pooled, individual patient data (n = 13,475) from six prospective, observa-
tional studies across the Northern Hemisphere [16], which included Canada [40], 
Italy [42], the Netherlands [41], Spain [39], the US [44], and a multinational cohort 
comprising subjects from Europe, the Middle East, North America, and Asia [45]. 
The RST was externally validated against a further study from Ireland (n = 1078) 
[43]. The RST includes three risk factors: birth 3 months before and 2 months 
after the RSV season start date; smokers in the household and/or smoking during 
pregnancy; and siblings (excluding multiples) and/or (planned) day-care (Figure 3)  
[16]. Predictive accuracy was demonstrated to be good, with an area under the 
receiver operating characteristic curve (AUROC) of 0.773, and sensitivity/specific-
ity of 68.9 and 73.0%, respectively. The RST provides cut-off scores for infants 
at low- (≤19; 1.0% RSVH rate), moderate- (20–45; 3.3%), and high-risk (50–56; 
9.5%) for RSVH [16].
The cost-effectiveness of using the multinational RST has not been formally 
assessed; however, economic evaluations have been undertaken on the use of other 
RSTs or risk-factor based approaches to targeting prophylaxis in late preterm 
33–35 wGA infants [19, 67, 68]. The Canadian RST, based on data from the PICNIC 
study [40], included seven variables: small for GA (<10th percentile); male sex; born 
early during the RSV season (November, December, January); family history with-
out eczema; subject or siblings in daycare; >5 individuals in the home, including the 
subject; and, >1 smoker in the household [17]. The AUROC was 0.762 and sensitivity 
and specificity were 68.2 and 71.9%, respectively. The RST included cut-off scores 
of 0–48, 49–64, and 65–100 for low-, moderate-, and high-risk infants, respectively 
Figure 3. 
Risk factor scoring tool for late preterm infants [16]. 0 = No/Not Present; 1 = Yes/Present for one risk factor; 
2 = Yes/Present for both risk factors. Score—Low-risk: ≤19; Moderate-risk: 20–45; High-risk: 50–56.
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[17]. A cost-effective analysis from 2008, using a decision analytic model, reported 
incremental cost-effectiveness ratios (ICERs) of CDN$179,699, CDN$34,215, and 
CDN$5765 per quality-adjusted life year (QALY) for low-, moderate-, and high-risk 
infants, respectively; the ICERs for moderate- and high-risk infants were consid-
ered cost-effective under the Canadian healthcare system (medications commonly 
adopted with ICERs per QALY of CDN$50–75,000 at that time) [19]. The Dutch RST 
was based on data from the RISK study and included four variables: family atopy; 
birth Aug-14 to Dec-01; breastfeeding; and siblings or daycare attendance [41]. 
The AUROC was 0.703 and the cut-off score for low-risk was defined as <16 (3.5% 
RSVH rate) and for high-risk as ≥16 (10.0% RSVH rate) [41]. Assuming all high-risk 
infants would receive prophylaxis, a decision model analysis produced an ICER of 
€214,748 per QALY, for moderately preterm infants 32–35 wGA, which was consid-
ered not cost-effective at a threshold of €80,000 per QALY [67]. Another analysis on 
33–35 wGA infants, using data from the Spanish FLIP-2 study [39], assessed cost-
effectiveness based on infants having either 2 major risk factors and 2 minor risk 
factors (group A), 2 major and 1 minor risk factors (B), or 2 major risk factors (C) 
[68]. Major risk factors included chronological age < 10 weeks at the start of the RSV 
season or being born during the first 10 weeks of the season, school-age siblings or 
daycare attendance; whereas minor risk factors included maternal smoking during 
pregnancy and male sex [69]. Again using a decision analytic model, the incremental 
cost-utility ratio of €11,550.37, €14,177.18 and €13,937.61 per QALY gained for groups 
A, B and C, respectively, were derived and were deemed all highly cost-effective 
based on a threshold of €30,000 per QALY from both a National Health System and 
societal perspective [68]. An Austrian analysis reported palivizumab prophylaxis 
to be cost-effective in 33–35 wGA infants at €21,862 per QALY from the healthcare 
system perspective, when administered to those <3 months of age with risk fac-
tors [70]. It is important to note that the Canadian, Spanish and Austrian analyses 
modeled the effects of long-term respiratory morbidity, using life-time (Canadian 
and Austrian) and 6-year time horizons (Spanish), while the Dutch study included 
follow-up to only 1 year of age [19, 67, 68, 70]. This could, in part, account for the 
differences in cost-effectiveness reported. It would be interesting to see the impact 
on the ICERs if the increased rates of wheezing in children with a history of RSVH 
at 6 years in the RISK study (27.7 vs. 17.6% for non-hospitalized) were incorporated 
into the Dutch cost-effectiveness analysis. The ICERs reported from all three studies 
reflect costs from the healthcare system or payer perspective; including the societal 
impact of RSVH could potentially reduce the ICERs by 15–40% [19, 68]. The models 
also do not include the impact of RSV in the community setting, which could reduce 
the ICERs still further.
4. Conclusion
There is a sizable body of evidence demonstrating that late preterm infants 
are at increased risk of RSVH, resulting in substantial morbidity, both in terms 
of acute hospitalization and longer-term respiratory sequelae. While we await the 
availability of a safe and effective vaccine or a newer monoclonal antibody with an 
extended half-life, palivizumab remains the only proven therapy for reducing the 
incidence of RSVH in late preterm infants, and may also reduce subsequent wheez-
ing. The use of RSTs and risk factors provides a mechanism to cost-effectively 
target the most vulnerable of these infants to receive palivizumab. It is recom-
mended that countries adopt the multinational RST (Figure 3) and adapt this with 
local data and cut-offs, as available, to meet country-specific requirements and 
available funding.
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Infants and children suffering from congenital heart disease represent a 
patient cohort particularly at risk for severe RSV infections. Most notably the 
complication rates in lower respiratory tract infections due to RSV among patients 
with congenital heart disease are significantly higher compared to other patient 
collectives. Predisposing factors are altered lung mechanics caused by either 
increased or decreased pulmonary blood flow, both resulting in a ventilation/
perfusion mismatch causing decreased pulmonary compliance and higher airway 
resistance. Randomized controlled trials have shown that immunoprophylaxis 
with palivizumab is beneficial for CHD patients. Guidelines from different 
national societies suggest administration of palivizumab for infants with CHD in 
young age injected monthly throughout the RSV season, if the CHD is considered 
hemodynamically significant.
Keywords: congenital heart disease (CHD), respiratory syncytial virus (RSV), 
palivizumab, immunoprophylaxis, lower respiratory tract infection (LRTI), 
bronchiolitis
1. Introduction
The burden of respiratory syncytial virus (RSV) infections differs markedly 
between patients. Clinical symptoms might be mild as in a common cold, while at 
the other end of the spectrum, children suffer from serious complications  
and negative impact with chronic respiratory problems that can persist into 
adulthood [1].
Since the 1980s infants and young children with congenital heart defects 
(CHD) have been shown to be a particularly vulnerable population developing 
severe lower respiratory tract infections (LRTIs) caused by RSV. The severity of 
infections in children with CHD was significantly higher than severity in children 
without CHD [2].
This chapter will provide an overview of the current state of knowledge regard-
ing RSV infections in children with CHD. In particular, we try to elucidate the 
mechanisms for the susceptibility of children with congenital heart defects to 
experience critical illness from RSV LRTI.
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2. Mechanisms of susceptibility caused by congenital heart disease
In general pulmonary compliance and airway resistance determine the breath-
ing. The airways of young infants have greater airway resistance due to their smaller 
diameter. Spontaneous breathing of infants is characterized by a functional residual 
capacity that is less than the closing capacity, which leads to areas of mechanical 
collapse of the alveoli. As a result the infant itself is more susceptible to develop 
ventilation/perfusion mismatch and is at higher risk for respiratory problems just 
from anatomy and pathophysiology irrespective of congenital heart disease [3].
As cardiac and pulmonary function is closely related, the baseline risk of the 
young infant is increased by several predisposing factors due to CHD.
Pulmonary sequelae and complications of CHD can be anatomical due to 
compression of the lung by, e.g., cardiomegaly, subsequently causing atelectases 
or airway malacia. Surgical or anesthesiologic trauma can result in chylothorax, 
subglottic stenosis, and laryngeal or phrenic nerve palsy leading to respiratory 
distress [4].
On the other hand, in particular the altered hemodynamics in CHD contributes 
to an increased vulnerability of the lung. In this context cardiac defects can be 
categorized in three main categories: (1) those with left-to-right shunt lesions, (2) 
those with right-to-left shunt lesions, and (3) those with more complex mixing 
patterns [5].
2.1 Left-to-right shunt lesions: pulmonary overflow
Typically CHDs with left-to-right shunt are acyanotic. They include atrial septal 
defects (ASDs), ventricular septal defects (VSDs), patent ductus arteriosus (PDA), 
atrioventricular septal defects (AVSDs), or double outlet right ventricles (DORV) 
with normally related great vessels (i.e., with VSD physiology). Very rarely coronary 
fistula or other extracardiac shunts are detected to cause volume overload of the 
right heart and the lungs.
When there is unrestricted communication between systemic and pulmonary 
circulation, the shunt volume is depending on the relative resistance in the two cir-
cuits with physiologically lower pulmonary resistance. During the normal transition 
of an infants’ blood circulation in the first months of life, the decrease of pulmo-
nary arteriolar resistance leads to an increase of left-to-right shunt. As a result the 
pulmonary blood flow is increasing (see Figure 1). Subsequently the lung volume 
and pulmonary artery pressure are elevated, and finally the capillary and left atrial 
pressures increase. At the end lung edema develops with high lung resistance. 
Alveolar edema and thus higher lung weight result in reduced lung compliance and 
therefore a decreased ventilation/perfusion ratio leading to intrapulmonary mis-
match and eventually hypoxemia.
2.2 Right-to-left shunt lesions: diminished pulmonary flow
Intracardiac right-to-left shunt leads to cyanosis. The basic pathophysiology of 
the most frequent cyanotic CHD is the tetralogy of Fallot (TOF) and includes an 
unrestricted communication between systemic and pulmonary circulation (VSD) 
and obstruction of the pulmonary outlet (see Figure 2). In these patients the main 
hemodynamic difference is reduced pulmonary blood flow, therefore lower lung 
volume and hypoplastic airways. The hypoplastic airways are more susceptible 
to obstruction and lead to higher airway resistance. Ventilation/perfusion ratio 
is increased in these patients causing dead space ventilation, which aggravates an 
already preexisting hypoxemia.
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2.3 Complex CHD with mixed physiology
In patients with complex CHD, cyanosis and relatively increased pulmonary 
blood flow may occur at the same time. Examples are hypoplastic left heart 
Figure 1. 
VSD. Pulmonary overflow due to left-to-right shunt through a ventricular septal defect (VSD).
Figure 2. 
TOF. Cyanosis due to right-to-left shunt through a VSD when pulmonary stenosis and hypoplastic pulmonary 
arteries are present in tetralogy of Fallot (TOF).
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2.3 Complex CHD with mixed physiology
In patients with complex CHD, cyanosis and relatively increased pulmonary 
blood flow may occur at the same time. Examples are hypoplastic left heart 
Figure 1. 
VSD. Pulmonary overflow due to left-to-right shunt through a ventricular septal defect (VSD).
Figure 2. 
TOF. Cyanosis due to right-to-left shunt through a VSD when pulmonary stenosis and hypoplastic pulmonary 
arteries are present in tetralogy of Fallot (TOF).
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syndrome (Figure 3) or other forms of functionally single ventricle like hypoplastic 
right heart, tricuspid atresia, or pulmonary atresia. Insertion of systemic to pulmo-
nary shunt as part of the first stage of palliative surgery ideally leads to a balanced 
pulmonary and systemic perfusion but for the sake of an increased volume load and 
persisting cyanosis.
These patients are at high risk for ventilation-perfusion mismatch. In addition, 
impaired ventricular function may contribute to higher pulmonary venous pres-
sures leading to pulmonary venous congestion and subsequently lung edema and 
higher pulmonary artery pressures [3, 5].
Pulmonary hypertension is known to exacerbate these effects and represents a 
particular predisposing factor for fatal disease [6].
In the end many complex risk factors are responsible for the susceptibility of 
young CHD patients. Compromised cardiorespiratory status at baseline, altered 
pulmonary mechanics, potential cyanosis and/or pulmonary hypertension, and 
ventilation-perfusion mismatch can increase the negative effects of respiratory dis-
ease in this vulnerable patient cohort unable to compensate properly for intercur-
rent disease. The interplay of the distinct circulation in CHD and the consequences 
on lung architecture and function contribute to the elevated risk to which these 
patients are exposed by an RSV infection [5, 7].
3. RSV-related morbidity of children with CHD
RSV accounts for about 20% of all respiratory infections in children below 
the age of 5 years. Most infections occur in the first 2 years of life. In healthy term 
infants, hospitalization rates due to RSV LRTI range from 1 to 3%, mainly in the 
first 6 months of life. Among high-risk populations like preterm infants with or 
without bronchopulmonary dysplasia (BPD), infants with CHD, Down syndrome, 
neuromuscular disease, immunosuppressed children, or patients with severe 
immune deficiency syndromes, hospitalization rates increase up to 10% [8].
Figure 3. 
Norwood-I palliated HLHS. Excessive pulmonary perfusion via Sano shunt leads to relative overflow of  
the pulmonary arteries, dilated left atrium resulting in higher pulmonary vein pressure causing pulmonary 
vein congestion.
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As shown in a systematic review as part of the RSV Evidence—A Geographical 
Archive of Literature (REGAL) series published in 2017 including 38 studies 
reporting RSV-associated morbidity and mortality, the risk and burden of RSV in 
CHD still remain serious. RSV hospitalization rates were generally high in young 
children (<4 years) with CHD varying between 14 and 357/1000 patients. Infants 
(<2 years) with CHD had a more severe course of RSV infections than patients 
without CHD. Duration of hospital stay was 4.4–14 days, up to 53% of them requir-
ing intensive care. Case fatality rates of up to 3% were associated with RSV LRTIs in 
children with CHD. RSV infection in the perioperative period of cardiac surgery and 
nosocomial infections in ICUs also represent an important cause of morbidity [9].
A recent investigation in Austria analyzed data on RSV-related hospitalizations 
in infants and small children in their first three RSV seasons (November–April). 
The study was performed retrospectively and included children with CHD born 
between 2004 and 2008. The study cohort included 602 patients of whom 451 
(74.9%) had hemodynamically not significant CHD (HNS-CHD), 102 (16.9%) 
had acyanotic, and 49 (8.1%) had cyanotic hemodynamically significant CHD 
(HS-CHD). Pulmonary hypertension was present in 48 of 151 (31.8%) patients 
with hemodynamically significant CHD. Overall incidence of RSV-related hospi-
talizations was 9.6%. Hospitalization rates between hemodynamically significant 
(10.4%) and not significant CHD (7.3%) did not differ significantly. The median 
duration of hospitalization was 8.5 days, whereas in HS-CHD the length was 14 days 
compared to 7 days in HNS-CHD. These results demonstrate the more severe course 
of RSV infections in children with hemodynamically significant disease. The 
median duration of supplemental oxygen was 1 day (0–38 days). 22.4% of children 
were treated at the ICU; the median duration of ICU stay was 10 days (2–70 days), 
and the median duration of mechanical ventilation was 4 days (0–38 days). 
Children with hemodynamically significant disease and early heart surgery were 
less often hospitalized compared to those with delayed cardiac surgery [10].
In order to investigate case fatality rates in young children hospitalized because 
of RSV LRTIs, a systematic review of 34 articles was conducted in 2012. The case 
fatality rates for RSV-associated bronchiolitis and pneumonia among patient col-
lectives of children, who are at particular high risk, were compared. The subgroups 
included (1) preterm infants, born before 37 gestational weeks, (2) children with 
diagnosed bronchopulmonary dysplasia (BPD) within the first 2 years of life, and 
(3) children with diagnosed CHD within the first 2 years of life. Case fatality rate 
among preterm infants was 1.2% (0–8.3%, median 0%), among children with BPD 
4.1% (0–10.5%, median 7.0%) and among children with CHD 5.2% (2.0–37%, 
median 5.9%). While case fatality estimates among children not at high risk ranged 
from 0 to 1.5% (weighted mean 0.2%, median 0.0%), case fatality rates among 
children at elevated risk of RSV LRTI were significantly higher with the highest case 
fatality rate for children with diagnosed CHD [11].
All these papers underline the fact that infants and children with CHD especially 
when hemodynamically significant represent an extremely sensitive patient collec-
tive when it comes to RSV disease. Most strikingly they tend to have a more severe 
course and worse outcome of LRTIs due to RSV.
4. Prevention of RSV
RSV is the most common cause of LRTIs in infants and toddlers and under 
certain circumstances like in HS-CHD puts the children at elevated risk to develop 
respiratory or cardiac failure. Therefore, specific infection control measures are 
necessary to prevent severe RSV infections [12].
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from 0 to 1.5% (weighted mean 0.2%, median 0.0%), case fatality rates among 
children at elevated risk of RSV LRTI were significantly higher with the highest case 
fatality rate for children with diagnosed CHD [11].
All these papers underline the fact that infants and children with CHD especially 
when hemodynamically significant represent an extremely sensitive patient collec-
tive when it comes to RSV disease. Most strikingly they tend to have a more severe 
course and worse outcome of LRTIs due to RSV.
4. Prevention of RSV
RSV is the most common cause of LRTIs in infants and toddlers and under 
certain circumstances like in HS-CHD puts the children at elevated risk to develop 
respiratory or cardiac failure. Therefore, specific infection control measures are 
necessary to prevent severe RSV infections [12].
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Comprehensive hygiene measures are efficacious and cost-effective in preventing 
the spread of RSV and should always be advocated as a main prophylactic factor. Breast 
feeding and avoidance of exposure to tobacco and other smoke are further important 
facts in the prevention of RSV disease [13, 14]. Delayed day-care attendance in high-
risk populations may represent a preventive factor from acquiring RSV infections [15].
As mentioned above early surgical correction of CHD remains a prophylactic 
factor for severe RSV LRTI [10].
Although vaccine candidates have been in clinical evaluation for nearly 50 years, 
none, to date, have reached licensing. Palivizumab, a humanized monoclonal 
antibody, is currently the only intervention licensed for the prevention of severe 
RSV disease [8].
4.1 Palivizumab prophylaxis
In June 1998, palivizumab was licensed by the US Food and Drug Administration 
(FDA) for prevention of serious LRTI caused by RSV in pediatric patients, who are 
at increased risk of severe disease including young children suffering from CHD 
[16]. The efficacy and safety of palivizumab have been evaluated in many multi-
center randomized controlled trials as shown in the following data [17–19].
In 2003 a prospective, randomized, double-blind, placebo-controlled mul-
ticenter trial including 1287 children with CHD was published. The study was 
conducted in the RSV seasons 199–2002 (seventy-six centers in the USA, six in 
Canada, three in Sweden, four in Germany, six in Poland, four in France, and six in 
the UK). The primary objective was to compare the safety, tolerance, and efficacy of 
palivizumab with placebo. The secondary objectives were to determine the effect of 
monthly administered palivizumab on hospitalization outcomes (total hospitaliza-
tion duration, days with increased oxygen requirement, incidence, and total days 
of ICU stays and RSV-associated mechanical ventilation), as well as to describe 
the effect of cardiac bypass on serum palivizumab levels and determine the palivi-
zumab levels before the second and fifth doses.
Children aged less than 24 months, who had documented hemodynamically sig-
nificant CHD, not yet corrected or partially corrected, were included. Patients were 
randomly assigned 1:1 to receive either 5 monthly (every 30 days) intramuscular 
injections of 15 mg/kg body weight palivizumab or placebo. Children were followed 
for 150 days for hospitalization and occurrence of adverse events. Monthly prophy-
laxis with palivizumab was associated with a 45% relative reduction in RSV hos-
pitalization rate (9.7% in the placebo group, 5.3% in the palivizumab group). The 
length of total hospital stays was reduced by 56% (129 days in the placebo group vs. 
57.4 days in the palivizumab group), days with increased oxygen requirement were 
reduced by 73% (101.5 days placebo vs. 27.9 days palivizumab), days at ICU were 
reduced by 78%, and days on mechanical ventilation showed a 41% reduction.
Regarding safety and tolerability, the incidence of adverse events in the palivi-
zumab and placebo group was similar. None of the children had drug-related severe 
adverse events.
The effect of cardiopulmonary bypass on serum palivizumab levels showed a 
notable decrease (58%) of antibody titers making early restart of palivizumab injec-
tions necessary [17].
Another paper documenting the effects of palivizumab in subjects with CHD 
was published in 2008. During the RSV seasons 2000–2004, data from 19,548 sub-
jects who received immunoprophylaxis with palivizumab were collected prospec-
tively in the palivizumab outcomes registry. One thousand five hundred subjects 
with CHD (7.7% of the entire cohort) were enrolled. Seventy-one percent had 
acyanotic CHD. About 1.9% of patients prophylactically treated with palivizumab 
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were hospitalized because of RSV infections, compared to 1.2% of patients included 
in the registry without CHD, which are low hospitalization rates compared to 
hospitalization rates before immunoprophylaxis [18].
A further study evaluated the impact of palivizumab prophylaxis on RSV hospi-
talizations among children with hemodynamically significant CHD by comparing 
the outcome before and after palivizumab prophylaxis. The American Academy of 
Pediatrics (AAP) revised the bronchiolitis policy statement and recommended the 
use of palivizumab in children younger than 24 months old with hemodynamically 
significant CHD in 2003. California statewide hospital discharge data from years 2000 
to 2002 (pre-AAP policy revision) were compared to those from years 2004 to 2006 
(post-AAP policy revision). Overall RSV hospitalization rate was 71 per 10,000 chil-
dren younger than 2 years. 3.0% were children with CHD and 0.50% hemodynami-
cally significant CHD. HS-CHD patients accounted for 0.56% of RSV hospitalizations 
in 2000–2002, compared to 0.46% RSV hospitalizations in 2004–2006, which means 
a 19% reduction in RSV hospitalizations among HS-CHD patients after 2003 [19].
4.2 Recommendations for the use of palivizumab in RSV prevention
As shown in many trials, RSV infections still represent increased complication 
rates in high-risk populations like infants and young children with CHD [2, 10, 11, 20]. 
There is consensus that palivizumab currently is the only licensed immunoprophy-
laxis that can and should be offered [21–33].
In this subsection the guidelines and recommendations for palivizumab use 
in children with CHD in the German-speaking countries will be compared to the 
guidelines of the USA, the UK, and Canada [21–30].
Table 1 summarizes the most important points of the latest recommendations.
There are substantial differences particularly regarding the age groups of children 
with CHD, who shall or may receive immunoprophylaxis. All national committees 
agree on the fact that only children with hemodynamically significant CHD shall get 
palivizumab. Therefore, if the CHD is considered not hemodynamically significant, 
i.e., without indication for corrective surgery, intervention or cardiac medication, for 
example, small atrial septal defects (ASDs), small ventricular septal defects (VSDs), 
patent ductus arteriosus (PDA), mild aortic or pulmonary stenosis, or mild coarcta-
tion, there is no indication for palivizumab. After corrective surgery or interven-
tion is performed, there is no need of palivizumab anymore as the risk is no longer 
elevated, unless the patients require further cardiac medication or there are other 
risk factors for severe RSV disease. In this case, the administration of palivizumab 
after cardiopulmonary bypass shall be given as soon as the patient is stable.
The definition for hemodynamically significant CHD is not consistent through-
out the national recommendations.
All of them have in common that cyanotic CHD is considered significant, as well 
as the presence of pulmonary hypertension. While the recommendations in the 
USA suggest prophylaxis for moderate and severe pulmonary hypertension (PH), in 
Switzerland palivizumab shall just be offered for children with severe PH [25, 28].
The latest American Academy of Pediatrics (AAP) recommendations suggest 
prophylaxis for children, who are born within 12 months of onset of the RSV season 
and suffer from hemodynamically significant heart disease. Consultation with a 
cardiologist for decisions about prophylaxis is recommended for patients with cya-
notic heart disease. Children with acyanotic HS-CHD, who are receiving medica-
tion to control congestive heart failure and will require cardiac surgical procedures, 
and infants with moderate to severe pulmonary hypertension, as well as children 
younger than 2 years who undergo cardiac transplantation during the RSV season 
may be considered for palivizumab prophylaxis [25].
The Burden of Respiratory Syncytial Virus Infection in the Young
52
Comprehensive hygiene measures are efficacious and cost-effective in preventing 
the spread of RSV and should always be advocated as a main prophylactic factor. Breast 
feeding and avoidance of exposure to tobacco and other smoke are further important 
facts in the prevention of RSV disease [13, 14]. Delayed day-care attendance in high-
risk populations may represent a preventive factor from acquiring RSV infections [15].
As mentioned above early surgical correction of CHD remains a prophylactic 
factor for severe RSV LRTI [10].
Although vaccine candidates have been in clinical evaluation for nearly 50 years, 
none, to date, have reached licensing. Palivizumab, a humanized monoclonal 
antibody, is currently the only intervention licensed for the prevention of severe 
RSV disease [8].
4.1 Palivizumab prophylaxis
In June 1998, palivizumab was licensed by the US Food and Drug Administration 
(FDA) for prevention of serious LRTI caused by RSV in pediatric patients, who are 
at increased risk of severe disease including young children suffering from CHD 
[16]. The efficacy and safety of palivizumab have been evaluated in many multi-
center randomized controlled trials as shown in the following data [17–19].
In 2003 a prospective, randomized, double-blind, placebo-controlled mul-
ticenter trial including 1287 children with CHD was published. The study was 
conducted in the RSV seasons 199–2002 (seventy-six centers in the USA, six in 
Canada, three in Sweden, four in Germany, six in Poland, four in France, and six in 
the UK). The primary objective was to compare the safety, tolerance, and efficacy of 
palivizumab with placebo. The secondary objectives were to determine the effect of 
monthly administered palivizumab on hospitalization outcomes (total hospitaliza-
tion duration, days with increased oxygen requirement, incidence, and total days 
of ICU stays and RSV-associated mechanical ventilation), as well as to describe 
the effect of cardiac bypass on serum palivizumab levels and determine the palivi-
zumab levels before the second and fifth doses.
Children aged less than 24 months, who had documented hemodynamically sig-
nificant CHD, not yet corrected or partially corrected, were included. Patients were 
randomly assigned 1:1 to receive either 5 monthly (every 30 days) intramuscular 
injections of 15 mg/kg body weight palivizumab or placebo. Children were followed 
for 150 days for hospitalization and occurrence of adverse events. Monthly prophy-
laxis with palivizumab was associated with a 45% relative reduction in RSV hos-
pitalization rate (9.7% in the placebo group, 5.3% in the palivizumab group). The 
length of total hospital stays was reduced by 56% (129 days in the placebo group vs. 
57.4 days in the palivizumab group), days with increased oxygen requirement were 
reduced by 73% (101.5 days placebo vs. 27.9 days palivizumab), days at ICU were 
reduced by 78%, and days on mechanical ventilation showed a 41% reduction.
Regarding safety and tolerability, the incidence of adverse events in the palivi-
zumab and placebo group was similar. None of the children had drug-related severe 
adverse events.
The effect of cardiopulmonary bypass on serum palivizumab levels showed a 
notable decrease (58%) of antibody titers making early restart of palivizumab injec-
tions necessary [17].
Another paper documenting the effects of palivizumab in subjects with CHD 
was published in 2008. During the RSV seasons 2000–2004, data from 19,548 sub-
jects who received immunoprophylaxis with palivizumab were collected prospec-
tively in the palivizumab outcomes registry. One thousand five hundred subjects 
with CHD (7.7% of the entire cohort) were enrolled. Seventy-one percent had 
acyanotic CHD. About 1.9% of patients prophylactically treated with palivizumab 
53
Respiratory Syncytial Virus Infections among Children with Congenital Heart Disease
DOI: http://dx.doi.org/10.5772/intechopen.85552
were hospitalized because of RSV infections, compared to 1.2% of patients included 
in the registry without CHD, which are low hospitalization rates compared to 
hospitalization rates before immunoprophylaxis [18].
A further study evaluated the impact of palivizumab prophylaxis on RSV hospi-
talizations among children with hemodynamically significant CHD by comparing 
the outcome before and after palivizumab prophylaxis. The American Academy of 
Pediatrics (AAP) revised the bronchiolitis policy statement and recommended the 
use of palivizumab in children younger than 24 months old with hemodynamically 
significant CHD in 2003. California statewide hospital discharge data from years 2000 
to 2002 (pre-AAP policy revision) were compared to those from years 2004 to 2006 
(post-AAP policy revision). Overall RSV hospitalization rate was 71 per 10,000 chil-
dren younger than 2 years. 3.0% were children with CHD and 0.50% hemodynami-
cally significant CHD. HS-CHD patients accounted for 0.56% of RSV hospitalizations 
in 2000–2002, compared to 0.46% RSV hospitalizations in 2004–2006, which means 
a 19% reduction in RSV hospitalizations among HS-CHD patients after 2003 [19].
4.2 Recommendations for the use of palivizumab in RSV prevention
As shown in many trials, RSV infections still represent increased complication 
rates in high-risk populations like infants and young children with CHD [2, 10, 11, 20]. 
There is consensus that palivizumab currently is the only licensed immunoprophy-
laxis that can and should be offered [21–33].
In this subsection the guidelines and recommendations for palivizumab use 
in children with CHD in the German-speaking countries will be compared to the 
guidelines of the USA, the UK, and Canada [21–30].
Table 1 summarizes the most important points of the latest recommendations.
There are substantial differences particularly regarding the age groups of children 
with CHD, who shall or may receive immunoprophylaxis. All national committees 
agree on the fact that only children with hemodynamically significant CHD shall get 
palivizumab. Therefore, if the CHD is considered not hemodynamically significant, 
i.e., without indication for corrective surgery, intervention or cardiac medication, for 
example, small atrial septal defects (ASDs), small ventricular septal defects (VSDs), 
patent ductus arteriosus (PDA), mild aortic or pulmonary stenosis, or mild coarcta-
tion, there is no indication for palivizumab. After corrective surgery or interven-
tion is performed, there is no need of palivizumab anymore as the risk is no longer 
elevated, unless the patients require further cardiac medication or there are other 
risk factors for severe RSV disease. In this case, the administration of palivizumab 
after cardiopulmonary bypass shall be given as soon as the patient is stable.
The definition for hemodynamically significant CHD is not consistent through-
out the national recommendations.
All of them have in common that cyanotic CHD is considered significant, as well 
as the presence of pulmonary hypertension. While the recommendations in the 
USA suggest prophylaxis for moderate and severe pulmonary hypertension (PH), in 
Switzerland palivizumab shall just be offered for children with severe PH [25, 28].
The latest American Academy of Pediatrics (AAP) recommendations suggest 
prophylaxis for children, who are born within 12 months of onset of the RSV season 
and suffer from hemodynamically significant heart disease. Consultation with a 
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The dosage of palivizumab is 15 mg/kg body weight in all recommendations. 
Prophylaxis shall be provided in the RSV season, which in the northern hemisphere 
is November until March, with slight differences in some US areas. Five monthly 
doses of the antibody shall be administered to provide antibody levels for 6 months.
Another important factor is to improve compliance by parental education. A 
large study from the Canadian registry of palivizumab found out that adherence to 
the monthly injection regimen was significantly associated with a lower incidence 
of RSV infections [34].
4.3 Pharmacoeconomics
Due to the high costs of palivizumab, which exceed the costs of RSV-related hos-
pitalizations, the cost-effectiveness of the product is considered controversial [19].
A cost-utility trial performed in Spain published in 2017 estimated the cost-
effectiveness of immunoprophylaxis with palivizumab versus placebo among 
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children with CHD. It concluded not only costs of hospitalization but also the 
impact of delayed cardiac surgery and the complications of performed surgery 
despite infections. The sequelae of asthma and allergic sensitization were put into 
calculation as well as indirect costs like parental absence from work. The model 
demonstrated that palivizumab prophylaxis results in more quality-adjusted life 
years (QALY) than placebo in children with CHD. Palivizumab prophylaxis was 
shown to be a cost-effective health-care intervention according to the commonly 
accepted standards of cost-effectiveness in Spain [35].
A nationwide cost-utility study based on epidemiological data over 16 RSV 
seasons performed in Austria compared the costs per QALY years in high-risk 
populations. Overall these long-term epidemiological data suggest that palivizumab 
is cost-effective in the prevention of RSV diseases in all groups. The results showed 
lowest costs per QALY years in patients with CHD (8484€) compared to 26,212€ in 
preterms and 24,654€ in BPD patients [36].
Data on cost-effectiveness still remains controversial but considering the limited 
treatment strategies for severe RSV infections and possible severe consequences in 
this especially vulnerable patient cohort may actually justify the costs of this only 
licensed immunoprophylaxis.
5. Conclusion
LRTIs caused by RSV among children with CHD put patients under high risk of 
developing respiratory or congestive heart failure. Regarding the increased fatality 
rates of RSV infections among infants and young children with CHD, immunoprophy-
laxis with palivizumab may be justified in this patient collective. Used properly (start-
ing in time with regular repetitions throughout the RSV season) palivizumab leads to 
a significant decrease in RSV-related hospitalization rates, as well as ICU days, days on 
mechanical ventilation, and days on supplemental oxygen. Unless a vaccine against 
RSV is found, immunoprophylaxis with palivizumab remains the only way to reduce 
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The dosage of palivizumab is 15 mg/kg body weight in all recommendations. 
Prophylaxis shall be provided in the RSV season, which in the northern hemisphere 
is November until March, with slight differences in some US areas. Five monthly 
doses of the antibody shall be administered to provide antibody levels for 6 months.
Another important factor is to improve compliance by parental education. A 
large study from the Canadian registry of palivizumab found out that adherence to 
the monthly injection regimen was significantly associated with a lower incidence 
of RSV infections [34].
4.3 Pharmacoeconomics
Due to the high costs of palivizumab, which exceed the costs of RSV-related hos-
pitalizations, the cost-effectiveness of the product is considered controversial [19].
A cost-utility trial performed in Spain published in 2017 estimated the cost-
effectiveness of immunoprophylaxis with palivizumab versus placebo among 
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RSV: Available Prophylactic 
Options and Vaccines in Clinical 
Trials
Debra T. Linfield and Fariba Rezaee
Abstract
Respiratory syncytial virus (RSV) is the leading cause of serious lower respira-
tory infection (ALRI)-related hospitalization in children worldwide, and a source of 
morbidity and mortality in high-risk adults. There are strong associations between 
RSV, persistent wheezing and childhood asthma. Despite extensive research, no 
effective treatment is available aside from supportive care. The trial of a formalin-
inactivated RSV vaccine in the 1960s resulted in priming the severe illness upon 
natural infection. Palivizumab, a monoclonal antibody approved for RSV prophy-
laxis in high-risk infants, has only moderately decreased hospital admissions due to 
RSV infection. Live-attenuated, vector, and protein-based vaccine candidates are 
being investigated in many clinical trials. Developing a vaccine remains challenging 
due to finding the right balance between adequate immunogenicity and attenua-
tion of vaccine. Here we review the clinical significance of RSV in infants, young 
children, high-risk adults, elderly population, pregnant women; clinical manifesta-
tions and consequences of RSV infection; the pharmacologic strategies currently 
available, the current stages of RSV vaccine clinical trials, different strategies, and 
major hurdles in the development of an effective RSV vaccine.
Keywords: respiratory syncytial virus (RSV), pediatric, respiratory infection, 
palivizumab, antiviral therapy, immuno-prophylaxis, RSV vaccine, clinical trials
1. Introduction
RSV, a member of the Paramyxoviridae family, is an enveloped, negative-
sense, single-stranded RNA virus [1]. Especially within the winter months, it is an 
important cause of morbidity and mortality among young children, the elderly, 
and immunocompromised individuals [2]. Infection is transmitted by either direct 
or indirect contact with respiratory droplets, and prior infection does not result in 
persistent immunity.
RSV accounts for approximately 2.1 million outpatient visits among children 
younger than 5 years old [3]. Additionally, there are 177,000 hospitalizations and 
14,000 deaths among adults older than 65 years due to RSV infection [4, 5] each 
year in the United States. Human studies have shown strong associations between 
RSV, persistent wheezing, and childhood asthma [6–8].
Symptoms usually begin 4–6 days after transmission and present with nasal 
congestion, rhinorrhea, fever, or cough. RSV is one of the leading causes of lower 
respiratory tract infection (LRTI), and can cause tachypnea, wheeze, hypoxemia, or 
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natural infection. Palivizumab, a monoclonal antibody approved for RSV prophy-
laxis in high-risk infants, has only moderately decreased hospital admissions due to 
RSV infection. Live-attenuated, vector, and protein-based vaccine candidates are 
being investigated in many clinical trials. Developing a vaccine remains challenging 
due to finding the right balance between adequate immunogenicity and attenua-
tion of vaccine. Here we review the clinical significance of RSV in infants, young 
children, high-risk adults, elderly population, pregnant women; clinical manifesta-
tions and consequences of RSV infection; the pharmacologic strategies currently 
available, the current stages of RSV vaccine clinical trials, different strategies, and 
major hurdles in the development of an effective RSV vaccine.
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1. Introduction
RSV, a member of the Paramyxoviridae family, is an enveloped, negative-
sense, single-stranded RNA virus [1]. Especially within the winter months, it is an 
important cause of morbidity and mortality among young children, the elderly, 
and immunocompromised individuals [2]. Infection is transmitted by either direct 
or indirect contact with respiratory droplets, and prior infection does not result in 
persistent immunity.
RSV accounts for approximately 2.1 million outpatient visits among children 
younger than 5 years old [3]. Additionally, there are 177,000 hospitalizations and 
14,000 deaths among adults older than 65 years due to RSV infection [4, 5] each 
year in the United States. Human studies have shown strong associations between 
RSV, persistent wheezing, and childhood asthma [6–8].
Symptoms usually begin 4–6 days after transmission and present with nasal 
congestion, rhinorrhea, fever, or cough. RSV is one of the leading causes of lower 
respiratory tract infection (LRTI), and can cause tachypnea, wheeze, hypoxemia, or 
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respiratory distress, resulting in an emergency department visit or hospital admis-
sion [9]. Males are more severely affected than females, and for reasons that are not 
fully elucidated, Native Americans and Alaskan Native children are more likely than 
children of other ethnicities to have severe infection requiring hospitalization.
To date, supportive care is the main treatment option for RSV admission [9, 10]. 
There is no vaccine approved for RSV prophylaxis in the general population. In 
1966, the first vaccine for RSV, a formalin-inactivated (FI-RSV) type, was devel-
oped. However, it resulted in vaccine-enhanced disease (VED). Among vaccinated 
infant, 80% developed severe bronchiolitis or pneumonia and two died, compared 
to only 5% for the placebo group [11]. There was increased eosinophilic and neu-
trophilic infiltration and mononuclear cells in the lung parenchyma found in the 
autopsies of two infants that died, which suggests a Th2-biased immune response, 
however the mechanism of the VED remains unclear [12].
RSV is composed of 10 genes encoding 11 proteins: small hydrophobic (SH) protein, 
nucleocapsid associated proteins N, P, L, M2–1, and M2–2, the matrix (M)  
protein, nonstructural proteins NS1 and NS2, glycoprotein (G), and fusion (F) pro-
tein. The SH, N, M2–2, NS2, G, and F proteins are the most commonly manipulated 
proteins in vaccine production (Figure 1). The SH protein inhibits cell apoptosis 
through inhibition of the TNF-α pathway [13]. The N protein initiates encapsidation 
of the genome, the M2–2 protein mediates the balance between transcription and 
RNA replication, and the NS2 protein inhibits host interferon (IFN) response [14, 
15]. G protein mediates viral attachment to the host cell, while F protein enables 
fusion of the virus [16, 17]. RSV A and RSV B, the two antigenic subtypes, differ in 
their amino acid sequence of the G protein and reactivity to antibodies, resulting in 
differences in disease severity [18]. Targeting the F protein is of particular interest, 
as it is highly conserved between the two antigenic subgroups.
In this chapter, we will discuss the current and candidate antiviral drugs and 
prophylactic agents against RSV infection and some of the ongoing clinical trials of 
RSV vaccines. Evaluation of drugs typically proceeds in a methodical order, from 
studies in healthy adults, to hospitalized adults, to older seropositive children, to 
Figure 1. 
Current and future options for RSV treatment or prophylaxis. No RSV vaccine is currently on the market, but 
diverse vaccine candidates, targeting different proteins within the RSV virion, are undergoing clinical trials.
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seronegative infants/toddlers. For purposes of this chapter, we will highlight the 
most recent trials where research is ongoing. We will also elucidate many of the com-
plex hurdles that have impeded progress in the development of an effective vaccine.
2. Available pharmacologic strategies
2.1 Ribavirin
Ribavirin, a synthetic guanosine analogue antiviral agent, was first synthesized in 
the 1970s. It is believed that ribavirin is phosphorylated intracellularly and can then 
disrupt purine metabolism by inhibiting inosine monophosphate dehydrogenase, 
thereby inhibiting nucleic acid synthesis. Furthermore, it promotes antiviral cytokine 
production and Type 1 T-cell mediated immune responses. Starting in 1993, the 
American Academy of Pediatrics (AAP) Committee on Infectious Diseases supported 
the use of Ribavirin for severe RSV infections. However, in 1996, the recommenda-
tion changed to “may be considered” [19]. Currently, the use of aerosolized Ribavirin 
is limited to immunocompromised patients with RSV due to the inconvenient route 
of delivery, which requires prolonged aerosol administration; risks for potential 
toxicity, such as teratogenic effects during pregnancy; cost of therapy; and need for 
hospital admission. The safety of oral ribavirin in moderately to severely immuno-
compromised adults with PCR-proven RSV infection was examined in a retrospective 
cohort study. The main outcome of this study was the rate of adverse events, and 
authors conclude that ribavirin is well tolerated in immunocompromised adults [20]. 
However, the rate of progression of disease from URTI to the LRTI was not measured. 
In another retrospective study, immunosuppressed patients were given either oral, 
intravenous, aerosol or a combination of these treatments and showed that ribavirin 
therapy reduces progression from RSV URTI to LRTI [21]. In a similar study, Khanna 
et al. reported that 32% of patients who were treated with ribavirin progressed to 
LRTI compared to 68% of the untreated group [22]. Their study showed that oral 
ribavirin therapy was likely as effective as aerosolized therapy. However, because of 
the sample size and retrospective nature, neither of these studies could determine 
the precise role of ribavirin therapy in this patient population. In addition, ribavirin 
is being used for Hepatitis C infection, in conjunction with an interferon agent [23]. 
Furthermore, a recent study showed that ribavirin inhibited Zika virus replication 
and Zika virus-induced cell death in mammalian cells [24].
2.2 ALS-008176
ALS-008176, a prodrug of a cytidine nucleoside analogue, decreased viral 
load and more readily cleared RSV than placebo in a randomized, double-blind 
clinical trial in healthy adults [25]. However, participants’ preexisting immune 
memory, which may promote RSV clearance, was not assessed [26]. A randomized, 
double-blind Phase I study assessing both a single and multiple ascending dosing in 
hospitalized infants (Clinicaltrials.gov identifier #NCT02202356) was completed in 
February 2018, but results have not been published yet.
2.3 Presatovir
During viral entry, the F protein undergoes conformational changes to fuse with 
the host cell membrane [17]. Presatovir (GS-5806) is an orally bioavailable agent 
that inhibits these conformational changes, thereby blocking viral fusion [27].  
It was found in a Phase 2a trial with healthy adults (Clinicaltrials.gov identifier 
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2.2 ALS-008176
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load and more readily cleared RSV than placebo in a randomized, double-blind 
clinical trial in healthy adults [25]. However, participants’ preexisting immune 
memory, which may promote RSV clearance, was not assessed [26]. A randomized, 
double-blind Phase I study assessing both a single and multiple ascending dosing in 
hospitalized infants (Clinicaltrials.gov identifier #NCT02202356) was completed in 
February 2018, but results have not been published yet.
2.3 Presatovir
During viral entry, the F protein undergoes conformational changes to fuse with 
the host cell membrane [17]. Presatovir (GS-5806) is an orally bioavailable agent 
that inhibits these conformational changes, thereby blocking viral fusion [27].  
It was found in a Phase 2a trial with healthy adults (Clinicaltrials.gov identifier 
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#NCT01756482) to reduce viral load and severity of disease. However, it also 
caused low neutrophil counts and increased levels of alanine aminotransferase [27]. 
Despite these adverse events and because of its promise as an efficacious antiviral 
agent, a Phase 2b, randomized, double-blind trial in RSV-infected hospitalized 
adults was completed in April 2017 (Clinicaltrials.gov identifier #NCT02135614). 
The primary outcome was the time-weighted average change in RSV load from 
baseline to Day 5. There appeared to be no significant differences between 
Presatovir and placebo (−0.77 vs. −0.89, respectively, p value = 0.46).
3. Currently available and under development immuno-prophylaxis
3.1 RSV-IVIG
RSV Immunoglobulin (RSV-IVIG, RespiGam) is a pooled hyperimmune poly-
clonal immunoglobulin preparation made from donors with high titers of anti-RSV 
antibodies. RSV-IVIG significantly reduced morbidity and mortality in high-risk 
infants [28]. It was initially licensed in 1996, but taken off the market in 2004, due 
to the need for long intravenous infusion sessions and supervision in a hospital 
setting, high volume doses resulting in fluid overload in already at-risk infants, and 
potential risk for blood-borne pathogens [29]. Furthermore, immunizations with 
live-attenuated viruses, such as the measles/mumps/rubella (MMR) vaccine, need 
to be postponed until 9 months after RSV-IVIG infusion.
ALX-0171 is an inhaled trivalent nanobody that targets the RSV F protein [30].  
A Phase I/IIa in RSV-infected infants and toddlers was recently completed in 
February 2016 (Clinicaltrials.gov identifier #NCT02309320). A Phase II dose rang-
ing study RSV-infected hospitalized infants was recently completed in May 2018. 
Results from both studies have not been published yet.
3.2 Palivizumab and motavizumab
Palivizumab (Synagis), developed by MedImmune (Gaithersburg, MD, USA) in 
1998, is the only currently approved prophylaxis agent against RSV infection [31]. It 
has been shown to reduce severe RSV infections by 55% and reduce RSV hospitaliza-
tions by 50%. Palivizumab is a humanized monoclonal IgG1 antibody that recognizes 
the RSV F protein and is administered intramuscularly monthly, for a maximum of 
5 months, during the RSV season. It has no significant adverse side effects and other 
required live-attenuated vaccines can still be administered. However, because of the 
high cost, it is selectively given to high-risk infants: preterm infants born at <29 weeks 
of gestation; infants with chronic lung disease (CLD) of prematurity defined as 
gestational age <32 weeks of gestation and requirement of supplemental oxygen for the 
first 28 days of life; hemodynamically significant congenital heart disease; and might 
be considered for neuromuscular disorders that impair the airway clearance [32, 33].
Motavizumab (MEDI-524, Numax), an affinity-matured derivative of palivi-
zumab, was shown to be more efficient than palivizumab with higher virus neutral-
izing effects [34]. However, it failed to receive FDA approval due to lack of greater 
clinical efficacy compared to palivizumab and cutaneous hypersensitivity reactions 
in some treated infants [35].
3.3 Suptavumab
Suptavumab (REGN2222) completed a Phase III trial in July 2017 (Clinicaltrials.
gov identifier #NCT02325791). It is a human monoclonal IgG1 antibody against 
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RSV-F [36]. 1177 preterm infants for whom palivizumab was not recommended 
were randomly assigned to one of three groups: Group 1 received one dose of 
intramuscular suptavumab and one dose of placebo, Group 2 received two doses of 
suptavumab, and Group 3 received two doses of placebo. There were no significant 
differences between the three groups in terms of the primary outcome of prevent-
ing medically attended RSV infection up to Day 150 [36]. All further development 
of Suptavumab has been stopped.
3.4 MEDI8897
MEDI8897 is another recombinant human monoclonal antibody with a modified 
Fc region that extends its half-life. MEDI8897 is being developed as RSV prophylaxis 
for all infants. The phase I (Clinicaltrials.gov identifier #NCT02114268) of study 
recruited 136 healthy adults, who received either MEDI8897 or placebo intravenously 
or intramuscularly, a single dose of 300–3000 mg. The half-life of the antibody was 
85–117 days across the groups [37]. The phase Ib/IIa of the study, recruited healthy 
preterm infants with a gestational age of 32–35 weeks. The antibody group received as 
single intramuscular dose of 10–50 mg MEDI8897. The half-life of the antibody was 
62.5–72.9 days. The authors concluded that the antibody has a favorable safety profile 
and can be administered as single dose during RSV season [38]. A Phase IIb trial in 
preterm infants’ ineligible for Synagis was completed in 2018 and there is a plan for the 
Phase III trial in healthy full-term and late pre-term infants in 2019.
4. RSV vaccines under development
To date, there is no vaccine against RSV. Developing a vaccine against RSV remains 
a challenge, as the proper balance is required in eliciting an immune response, while 
avoiding vaccine-enhanced disease. While many of the proteins within RSV are being 
manipulated in different vaccine strategies, RSV F comprises a highly conserved 
amino acid sequence called antigenic site II, between RSV-A and RSV-B antigenic 
subgroups, and has been considered an important antigen for an RSV vaccine.
Designing a vaccine against RSV requires careful considerations. Infants, the 
elderly, and pregnant women are the three targeted populations for RSV vaccine 
development [39]. Each of the three types of vaccines, live-attenuated, vector 
delivery, and protein based, have benefits and drawbacks that have to be considered 
when developing vaccine technology (Table 1). Live-attenuated vaccines contain 
extracted components of viral proteins and present antigens most similarly to the 
naturally occurring infection [40]. They stimulate both humoral and cell-mediated 
immune responses. Live-attenuated vaccines are employed against many viral 
diseases, like measles, rubella, polio, rotavirus, varicella, and yellow fever.
Taken from: Rezaee F, Linfield DT, Harford TJ, Piedimonte G. Ongoing develop-
ments in RSV prophylaxis: a clinician’s analysis. Curr Opin Virol. 2017;24:70–78.)
One major drawback of live attenuated vaccines is that they cannot be given to 
patients with compromised immunity including pregnant woman. Vector-delivery 
system vaccines utilize a non-pathogenic virus genome with inserted portions of 
RSV proteins. Similar to live-attenuated vaccines, these vaccines increase mucosal 
IgA and cellular immune responses, yet without the risk of insufficient attenuation 
[40]. Protein-based vaccines include whole-inactivated viruses, subunit antigens, 
and particle-based vaccines. Live-attenuated or vector vaccines hold the greatest 
promise for infants due to the risk of vaccine-enhanced RSV disease. Pregnant 
women and the elderly are not susceptible to vaccine-enhanced RSV disease, and 
therefore protein-based RSV vaccines are likely the most effective candidates [40].
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Live-attenuated, vector, and protein-based vaccines each possess advantages and 
disadvantages. Because non-replicating vaccines may elicit enhanced disease in RSV-
naïve infants during subsequent infection, replicating or vectored vaccines might be 
a better choice in this group [41, 42]. Additionally, active immunization for infants 
is challenging due to passive immunity received from the mother [43]. Because of 
these factors, different vaccines may be required for different target populations. 
Understanding these complexities is crucial in RSV vaccine advancement. We will 
now discuss in depth the different vaccine strategies and current clinical trials in 
each category. A list of the vaccine candidates is summarized in Table 2.
Vaccine type Current strategies
















Modified Vaccinia Ankara vector
MVA-RSV
MVA-BN





Current vaccine candidates undergoing clinical trials.
Advantages Disadvantages
Live-attenuated




• Does not exacerbate future RSV 
exposure
• Administered intranasally
• Need to obtain delicate balance 




(For young infants 
and children 
<24 months of age)
• Induced potent cellular and 
humoral responses in a primate 
model and preclinical studies
• Safer option than live attenuated 
vaccines in children with no risk 
of insufficient attenuation
• Prior exposure to the vector and 
immunological memory against com-
mon serotypes may reduce the immune 
response and limit their use
• The potential oncogenicity and pathoge-




• Maternal immunization could 
increase transplacental antibody 
transfer and provide immunity 
for infants
• High risk of exacerbation for RSV-naïve 
infants
Table 1. 
Advantages and disadvantages of the main strategy categories for RSV vaccine development.
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4.1 Live-attenuated vaccines
The tragic results of the formalin-inactivated RSV vaccine in the 1960s spurred 
research in the development of live-attenuated vaccine candidates. The live virus 
has parts of the genome deleted and is passaged at gradually lower temperatures. 
Live-attenuated vaccines require a delicate balance: maintain sufficient viral 
genome RNA replication to illicit enough antibody response in RSV-naïve infants, 
yet with a low risk of deattenuation and no harmful effects [44]. Live-attenuated 
vaccines are, in theory, safe for RSV-naïve infants because it does not exacerbate 
future exposure to RSV. Furthermore, it may be administered intranasally, which 
can mimic a milder form of a natural infection, and lead to viral replication in the 
upper respiratory tract [40]. This will induce mucosal and humoral immunogenic-
ity, despite the potential presence of maternal antibodies acquired transplacentally.
Several live-attenuated RSV vaccine candidates have deletions of a large seg-
ment of the M2–2 gene. The M2–2 gene mediates the transition from transcription 
to RNA replication [14]. In vitro studies have shown that M2–2 gene deletion leads to 
decreased viral RNA replication, but increased F and G protein expression through 
transcription. This means that the virus is adequately attenuated, yet potentially 
could lead to augmentation of the neutralizing antibody response [14]. A Phase I 
study explored the safety of a LID ΔM2–2 vaccine, delivered intranasally to RSV-
seronegative infants (aged 6 to 24 months). This vaccine infected the subjects success-
fully, but the peak shedding titers were higher than wanted, and therefore the study 
was terminated [45, 46]. Further attenuation to the LID ΔM2–2 vaccine, to counter 
the high shedding titers, is currently under investigation. The LID ∆M2–21030s vac-
cine has a mutation conferring temperature sensitivity. A Phase I placebo-controlled 
study in RSV-seronegative infants aged 6 to 24 months (Clinicaltrials.gov identi-
fier #NCT02794870) completed in July 2017, showed that roughly 60% of vaccine 
recipients and 27% of placebo recipients had solicited adverse events. Conclusions 
regarding the LID ∆M2–21030s vaccine have not yet been made. A Phase I LID cp ∆M2– 
2 vaccine, which in comparison to the LID ∆M2–2 contains 5 amino acid substitu-
tions, was terminated early in seronegative infants 6 to 24 months of age due to 
indication that the vaccine “did not meet the protocol criteria for a good vaccine can-
didate” (ClinicalTrials.gov identifier #NCT02890381). We believe that this is because 
only 6/11 patients in the vaccine arm of the trial were infected with the vaccine virus 
from Study Day 0–28, thereby suggesting that there was not a strong enough immune 
response against the vaccine. Another vaccine candidate is RSV D46/NS2/N/∆M2–2-
HindIII that contains one point mutation in the NS2 and N proteins and a modified 
version of the M2–2 deletion [47]. A Phase I study in RSV-seronegative infants and 
children 6–24 months of age was completed in May 2018.
Aside from deleting the M2–2 gene, the NS2 gene is another potential “knock-
out” gene for a live-attenuated vaccine. The RSV NS2 gene is known to promote 
epithelial cell shedding and inhibit host IFN response [15]. ΔNS2/Δ1313/1314 L, 
a vaccine candidate with a deleted NS2 gene, is genetically stable and moderately 
temperature-sensitive [48]. Another candidate, RSV 6120/∆NS2/1030s, also has a 
deleted NS2 gene, in combination with the “1030s” missense mutation, which pro-
vides further restriction of replication. Both of these candidates are currently being 
assessed in both seropositive and seronegative children and infants (Clinicaltrials.
gov identifiers #NCT03422237 and #NCT03387137).
Strategies have also targeted the SH gene. The RSV SH gene has multiple func-
tions, including inhibiting cell apoptosis, inhibiting signals from TNF-α, and 
modifying membrane permeability [49]. One vaccine that has a complete dele-
tion of the SH gene, rA2cp248/404/1030∆SH, demonstrated restricted antibody 
response in the subjects, as well as viral genotypic and phenotypic instability 
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Live-attenuated, vector, and protein-based vaccines each possess advantages and 
disadvantages. Because non-replicating vaccines may elicit enhanced disease in RSV-
naïve infants during subsequent infection, replicating or vectored vaccines might be 
a better choice in this group [41, 42]. Additionally, active immunization for infants 
is challenging due to passive immunity received from the mother [43]. Because of 
these factors, different vaccines may be required for different target populations. 
Understanding these complexities is crucial in RSV vaccine advancement. We will 
now discuss in depth the different vaccine strategies and current clinical trials in 
each category. A list of the vaccine candidates is summarized in Table 2.
Vaccine type Current strategies
















Modified Vaccinia Ankara vector
MVA-RSV
MVA-BN





Current vaccine candidates undergoing clinical trials.
Advantages Disadvantages
Live-attenuated




• Does not exacerbate future RSV 
exposure
• Administered intranasally
• Need to obtain delicate balance 




(For young infants 
and children 
<24 months of age)
• Induced potent cellular and 
humoral responses in a primate 
model and preclinical studies
• Safer option than live attenuated 
vaccines in children with no risk 
of insufficient attenuation
• Prior exposure to the vector and 
immunological memory against com-
mon serotypes may reduce the immune 
response and limit their use
• The potential oncogenicity and pathoge-




• Maternal immunization could 
increase transplacental antibody 
transfer and provide immunity 
for infants
• High risk of exacerbation for RSV-naïve 
infants
Table 1. 
Advantages and disadvantages of the main strategy categories for RSV vaccine development.
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4.1 Live-attenuated vaccines
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a vaccine candidate with a deleted NS2 gene, is genetically stable and moderately 
temperature-sensitive [48]. Another candidate, RSV 6120/∆NS2/1030s, also has a 
deleted NS2 gene, in combination with the “1030s” missense mutation, which pro-
vides further restriction of replication. Both of these candidates are currently being 
assessed in both seropositive and seronegative children and infants (Clinicaltrials.
gov identifiers #NCT03422237 and #NCT03387137).
Strategies have also targeted the SH gene. The RSV SH gene has multiple func-
tions, including inhibiting cell apoptosis, inhibiting signals from TNF-α, and 
modifying membrane permeability [49]. One vaccine that has a complete dele-
tion of the SH gene, rA2cp248/404/1030∆SH, demonstrated restricted antibody 
response in the subjects, as well as viral genotypic and phenotypic instability 
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primarily due to reversion of the 1030 mutation [42, 48]. MEDI-559 differs from 
rA2cp248/404/1030∆SH by silent nucleotide substitutions throughout the viral 
genome [42, 50]. A Phase I/IIa trial studying the safety and efficacy of MEDI-559, 
showed a higher incidence of medically attended LRTI in RSV seronegative infants 
5 to <24 months of age and in infants 1 to <3 months of age regardless of baseline 
serostatus within 28 days, as compared to placebo [50]. RSV neutralizing antibod-
ies were detected in 59% of MEDI-559 recipients, in comparison to 9% of placebo 
subjects. Interestingly, this microneutralization response was lower than the 
rA2cp248/404/1030ΔSH vaccine’s response. Adverse events, most notably URTI, 
occurred in 67% MEDI-559 and 57% placebo recipients, which was not clinically 
significantly different. Further safety trials are warranted to determine the safety 
profile of MEDI-559 as there was increased incidence of medically attended LRTI.
In comparison to MEDI-559, RSVcps2 contains 5 nucleotide changes and 1 
amino acid substitution. The level of attenuation of RSVcps2 and MEDI-559 was 
shown to be similar in a study in seronegative chimpanzees [48]. This study also 
showed that it was temperature-sensitive and phenotypically and genetically 
stable. A Phase I trial in RSV-seronegative, healthy 6–24 month old children 
demonstrated that RSVcps2 is safe and effective [51]. Furthermore, unlike 
MEDI-559, medically attended LRTI was not observed. There were no signifi-
cant differences in the number of adverse events between the experimental and 
control groups. However, in comparison to rA2cp248/404/1030ΔSH, RSVcps2 
had decreased levels of replication and immunogenicity. The study investiga-
tors believe that this is due to the 37 silent nucleotide differences between the 
two vaccine candidates [51]. An ideal candidate would therefore combine the 
genetic stability of RSVcps2 and the greater replication and immunogenicity 
of rA2cp248/404/1030ΔSH. Other ∆SH vaccine candidates include OE4 (RSV-
A2-dNS1-dNS2-ΔSH-dGm-Gsnull-line19F) and DB1 (RSV-A2-dNS-ΔSH-BAF), 
which have both been found to be immunogenic in cotton rats [52, 53].
4.2 Vector delivery systems
Vaccine technology is currently utilizing adenovirus and non-pathogenic viral 
genomes that can act as immune potentiators of delivery systems. These vaccines 
contain inserted portions of RSV F, N, and M2–1 proteins [54]. Vector vaccines 
increase mucosal IgA and cellular immune responses similar to live-attenuated vac-
cine candidates, yet without the risk of insufficient attenuation [55]. Furthermore, 
adjuvants used with these vector vaccines could potentially enhance the immune 
response to the vaccine [56].
GlaxoSmithKline’s ChAd155-RSV (GSK3389245A) and GSK3003891A are RSV 
vaccine candidates encoded by a chimpanzee-derived adenovector. A Phase II trial 
(Clinicaltrials.gov identifier #NCT02360475) evaluating GSK3003891A in healthy, 
non-pregnant women aged 18–45 years was recently completed. The study showed 
that GSK3003891A is both safe and immunogenic. However, a Phase II trial in healthy 
pregnant women and infants born to vaccinated mothers was canceled due to instabil-
ity of the PreF antigen during manufacturing. A Phase I study investigating ChAd155-
RSV in healthy adults aged 18 to 45 years was recently completed (Clinicaltrials.gov 
identifier #NCT02491463), and a Phase II study in RSV-seropositive infants aged 
12–23 months is underway (Clinicaltrials.gov identifier #NCT02927873). Another 
adenoviral-vector based RSV vaccine candidate, VXA-RSV-f, expressing the F-protein 
and a dsRNA adjuvant, is recently completed a Phase I, placebo-controlled, dose-
ranging study, using subjects aged 18–49 years. Results have not been released yet.
Adenoviruses of serotype 26 (Ad26) are engineered to comprise a nucleotide 
sequence encoding RSV F protein, which showed efficacy against RSV in mice and 
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cotton rats [57]. Two Phase I, placebo-controlled studies assessed the administra-
tion of Ad26.RSV.FA2, given either once or twice, followed by Ad35.RSV.FA2, and 
vice versa, to adults aged 18–50 years. Ad26.RSV.FA2 was shown to be safe and well 
tolerated. There was also increased humoral and cellular immunity for 6 months. 
Ad26.RSV.preF differs by 5 amino acids and contains the pre-fusion conformation 
stabilized F protein, and showed increased immunogenicity in comparison to Ad26.
RSV.FA2 in pre-clinical studies [58]. It is currently undergoing a Phase II clinical 
trials in adults aged 18–50 years and RSV-seropositive toddlers aged 12–24 months 
(Clinicaltrials.gov identifier #NCT03303625) and in healthy adults greater than 
age 60 (Clinicaltrials.gov identifier #NCT03339713). PanAd3-RSV, a vaccine 
based on the RSV viral proteins F, N and M2–1 encoded by Simian Adenovirus, 
completed a Phase I trial in subjects 18–75 years of age (ClinicalTrials.gov identi-
fier #NCT01805921) in 2015, alongside a Modified Vaccinia Virus Ankara (MVA) 
non-replicating vector vaccine candidate. Both of these vector vaccines contain RSV 
viral proteins F, N and M2–1.
PanAd3-RSV and MVA-RSV were both safe and effective in cotton rats, mice, 
and calves [59] and immunogenic in a primate model [54]. Most adverse effects 
were mild to moderate, self-limiting at the site of injection and the study concluded 
that the vaccine was safe and immunogenic [60]. Despite the promising results, no 
current clinical trial is investigating these vaccine candidates. MVA-BN (modified 
Vaccinia Ankara—Bavarian Nordic) is another MVA-based vaccine undergoing 
investigation. In August 2018, Bavarian Nordic announced that in a Phase II trial 
in older adults the MVA-BN vaccine elicited broad antibody and T cell responses to 
both RSV subtypes that lasted 6 months. Furthermore, a booster shot 1 year later 
again initiated a robust cellular immune response [61].
4.3 Protein-based vaccines
Pregnant women and the elderly are not susceptible to vaccine-enhanced RSV 
disease like infants, and therefore RSV protein-based vaccines are most likely 
the most effective candidates. Protein-based vaccine candidates include whole-
inactivated viruses, subunit antigens, and particle-based vaccines. Vaccinating a 
pregnant woman can provide passive immunity to the fetus, as RSV-neutralizing 
antibodies have been shown to pass from mother to fetus in utero [43]. The higher 
RSV neutralizing antibody in cord blood was associated with reduced risk of hos-
pitalization and disease severity in RSV infection has been shown by several studies 
[62, 63]. A recent comprehensive study measured multiple serum neutralizing RSV 
of the infants presented with primary RSV infection and did not find a direct rela-
tionship between the disease severity and level of most of anti–respiratory syncytial 
virus (RSV) antibody titers. However, they found a significant inverse relationship 
between antibody titer to RSV F protein and disease severity [64]. This is particu-
larly important as the post-fusion form of RSV F protein has been used in clinical 
trial [65]. Additionally, experimental studies have shown that RSV infection during 
pregnancy can alter the offspring’s postnatal immunity and airway hyperresponsive-
ness [66]. Therefore, a protein-based vaccine not only provides immunization for the 
pregnant woman, but also for the fetus in utero and the offspring once baby is born.
MEDI-7510 is a subunit RSV vaccine candidate that contains the post-fusion F glyco-
protein, with or without a glucopyranosyl lipid A (a synthetic TLR-4 agonist) adjuvant 
[67]. A Phase IIb trial in adults aged 60 and older showed that the vaccine candidate was 
immunogenic but did not protect the study population from RSV illness [68].
Novavax’s RSV F-protein nanoparticle vaccine has been trialed in a few Phase I 
and II studies in healthy human adults and one study of subjects 24 to <72 months 
of age, and was found to be well-tolerated and immunogenic in all studies [69, 70]. 
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pregnant women and infants born to vaccinated mothers was canceled due to instabil-
ity of the PreF antigen during manufacturing. A Phase I study investigating ChAd155-
RSV in healthy adults aged 18 to 45 years was recently completed (Clinicaltrials.gov 
identifier #NCT02491463), and a Phase II study in RSV-seropositive infants aged 
12–23 months is underway (Clinicaltrials.gov identifier #NCT02927873). Another 
adenoviral-vector based RSV vaccine candidate, VXA-RSV-f, expressing the F-protein 
and a dsRNA adjuvant, is recently completed a Phase I, placebo-controlled, dose-
ranging study, using subjects aged 18–49 years. Results have not been released yet.
Adenoviruses of serotype 26 (Ad26) are engineered to comprise a nucleotide 
sequence encoding RSV F protein, which showed efficacy against RSV in mice and 
69
RSV: Available Prophylactic Options and Vaccines in Clinical Trials
DOI: http://dx.doi.org/10.5772/intechopen.84851
cotton rats [57]. Two Phase I, placebo-controlled studies assessed the administra-
tion of Ad26.RSV.FA2, given either once or twice, followed by Ad35.RSV.FA2, and 
vice versa, to adults aged 18–50 years. Ad26.RSV.FA2 was shown to be safe and well 
tolerated. There was also increased humoral and cellular immunity for 6 months. 
Ad26.RSV.preF differs by 5 amino acids and contains the pre-fusion conformation 
stabilized F protein, and showed increased immunogenicity in comparison to Ad26.
RSV.FA2 in pre-clinical studies [58]. It is currently undergoing a Phase II clinical 
trials in adults aged 18–50 years and RSV-seropositive toddlers aged 12–24 months 
(Clinicaltrials.gov identifier #NCT03303625) and in healthy adults greater than 
age 60 (Clinicaltrials.gov identifier #NCT03339713). PanAd3-RSV, a vaccine 
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fier #NCT01805921) in 2015, alongside a Modified Vaccinia Virus Ankara (MVA) 
non-replicating vector vaccine candidate. Both of these vector vaccines contain RSV 
viral proteins F, N and M2–1.
PanAd3-RSV and MVA-RSV were both safe and effective in cotton rats, mice, 
and calves [59] and immunogenic in a primate model [54]. Most adverse effects 
were mild to moderate, self-limiting at the site of injection and the study concluded 
that the vaccine was safe and immunogenic [60]. Despite the promising results, no 
current clinical trial is investigating these vaccine candidates. MVA-BN (modified 
Vaccinia Ankara—Bavarian Nordic) is another MVA-based vaccine undergoing 
investigation. In August 2018, Bavarian Nordic announced that in a Phase II trial 
in older adults the MVA-BN vaccine elicited broad antibody and T cell responses to 
both RSV subtypes that lasted 6 months. Furthermore, a booster shot 1 year later 
again initiated a robust cellular immune response [61].
4.3 Protein-based vaccines
Pregnant women and the elderly are not susceptible to vaccine-enhanced RSV 
disease like infants, and therefore RSV protein-based vaccines are most likely 
the most effective candidates. Protein-based vaccine candidates include whole-
inactivated viruses, subunit antigens, and particle-based vaccines. Vaccinating a 
pregnant woman can provide passive immunity to the fetus, as RSV-neutralizing 
antibodies have been shown to pass from mother to fetus in utero [43]. The higher 
RSV neutralizing antibody in cord blood was associated with reduced risk of hos-
pitalization and disease severity in RSV infection has been shown by several studies 
[62, 63]. A recent comprehensive study measured multiple serum neutralizing RSV 
of the infants presented with primary RSV infection and did not find a direct rela-
tionship between the disease severity and level of most of anti–respiratory syncytial 
virus (RSV) antibody titers. However, they found a significant inverse relationship 
between antibody titer to RSV F protein and disease severity [64]. This is particu-
larly important as the post-fusion form of RSV F protein has been used in clinical 
trial [65]. Additionally, experimental studies have shown that RSV infection during 
pregnancy can alter the offspring’s postnatal immunity and airway hyperresponsive-
ness [66]. Therefore, a protein-based vaccine not only provides immunization for the 
pregnant woman, but also for the fetus in utero and the offspring once baby is born.
MEDI-7510 is a subunit RSV vaccine candidate that contains the post-fusion F glyco-
protein, with or without a glucopyranosyl lipid A (a synthetic TLR-4 agonist) adjuvant 
[67]. A Phase IIb trial in adults aged 60 and older showed that the vaccine candidate was 
immunogenic but did not protect the study population from RSV illness [68].
Novavax’s RSV F-protein nanoparticle vaccine has been trialed in a few Phase I 
and II studies in healthy human adults and one study of subjects 24 to <72 months 
of age, and was found to be well-tolerated and immunogenic in all studies [69, 70]. 
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This vaccine consists of nearly the full-length F glycoprotein. This nanoparticle 
vaccine prompted transplacental antibody transfer within a guinea pig model [71]. 
Furthermore, in a Phase II study in healthy women of child-bearing age, the vaccine 
was well tolerated. The peak of Anti-F IgG antibody was day 14 and persisted for 
3 months, optimal for administration during the third trimester [72]. Recently, 
the immunogenicity, with an aluminum adjuvant, was evaluated in a Phase II trial 
(Clinicaltrials.gov identifier #NCT02247726) in healthy third-trimester pregnant 
women. In this study in pregnant women, the primary outcome measures were 
safety and immunogenicity of the vaccine, as well as its impact on the number of 
infants with medically-attended RSV LRTI and age of onset of the infection. No 
results have been posted for this study. However, a Phase III study investigation in 
the same study population is set to be completed in 2019, thereby suggesting that 
the Phase II trial met its goals.
5. Conclusions
RSV is one of the most common causes of lower respiratory disease in infants, 
young children, and the elderly. Treatment is currently limited to support-
ive care, such as supplemental oxygen, bronchodilators, or corticosteroids. 
Palivizumab prophylaxis is currently restricted to high-risk infants. There 
is currently no vaccine to prevent RSV infection. There are many challenges 
associated with developing an RSV vaccine candidate. When developing a live 
attenuated vaccine, an equilibrium must be struck between adequate immu-
nogenicity and attenuation of the virus. Non-replicating vaccines, like in some 
vector-delivery systems and protein-based vaccines, can enhance RSV infection 
in RSV-naïve infants. Therefore, it may be necessary to develop separate vaccines 
for each at-risk population: neonates and young children, pregnant women, and 
the elderly. One highly promising strategy appears to be maternal immunization 
with a nonreplicating vaccine, as this may provide protection during the first few 
months of life in the neonate.
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Respiratory syncytial virus (RSV) infection is a major cause of severe respiratory 
disease in infants and young children worldwide and also forms a serious threat for 
the elderly. Vaccination could significantly relieve the burden of the RSV disease. 
However, unfortunately there is no licensed vaccine available so far. This is partly 
due to disastrous outcome of a clinical trial of formalin-inactivated RSV (FI-RSV) 
in children in 1960s; leading to enhanced respiratory disease upon natural infection. 
These findings contributed significantly to the delay of RSV vaccine development. 
Other key obstacles in development of RSV vaccine such as a peak of severe disease 
at 2–3 months of age, challenging biochemical behavior of key vaccine antigens and 
dependence on animal models that may not truly reflect human disease processes. 
These challenges could be overcome through maternal immunization, structure-
based engineering of vaccine antigens, the design of a novel platform for safe infant 
immunization, and the development of improved animal models. Currently, several 
vaccine candidates are in pre-clinical and clinical trials targeting the diverse age 
groups; young children or older adults from the infection or can reduce incidence, 
mortality and morbidity among the RSV infected individuals.
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1. Introduction
Respiratory syncytial virus (RSV) infection is a major cause of lower respiratory 
tract diseases among infants, young children and immune-compromised individu-
als. RSV infection provides partial immunity and reinfection may occur often 
throughout life. Therefore, RSV infection forms a severe threat in chronically ill 
adults and the elderly [1]. Current studies have demonstrated that RSV also a main 
cause of mortality among the elderly, indeed to similar extents as does influenza 
[2]. Presently, the only approved medication against RSV infection is a prophylactic 
monoclonal antibody, i.e., Palivizumab, which is given as a prophylaxis to high-risk 
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infants [3]. Despite the isolation and characterization of the virus in 1956, efforts 
to develop a safe vaccine have been unsuccessful so far. In a clinical trial conducted 
in young children in the 1960s, a formalin-inactivated RSV (FI-RSV) vaccine did 
not protect against infection rather led to enhanced respiratory disease (ERD) upon 
subsequent exposure of the vaccinees to the natural virus. These findings that inac-
tivated RSV vaccines may prime for ERD has contributed significantly to the delay 
of vaccine development. Other major challenges for development of RSV vaccine 
are a disease severity at 2–3 months of age, challenging biochemical behavior of 
key vaccine antigens and dependence on animal models that may not exactly mimic 
human disease processes. These challenges could be overcome through maternal 
immunization, structure-based engineering of vaccine antigens, the design of a 
novel strategy for safe immunization of infants, and the development of better 
animal models (Table 1).
2. Respiratory syncytial virus
RSV is an enveloped non-segmented negative-sense single-stranded (ss) RNA 
virus belonging to the Orthopneumovirus genus and Pneumoviridae family [4]. Two 
serotypes of RSV have been recognized i.e., RSV A and RSV B [4].
The RSV genome comprises 10 genes of 15.2 kb nucleotides encodes 11 proteins 
[5]. RSV comprises of a nucleocapsid enclosed by a lipid envelope with a diameter 
of 150–300 nm (Figure 1: RSV particle and RSV-genome). RSV expresses two 
non-structural proteins such as NS1 and NS2. These are detected only in RSV-
infected cells and are not packaged into the virion. They mainly serve to inhibit type 
I interferon responses [7]. Eight RSV proteins are present in the virion particles. 
Among these structural proteins, three are membrane proteins: the attachment 






Goal: Prevent severe complications
Challenges: Less developed immune system; 
more susceptible to disease; FI-RSV enhanced 
respiratory disease history, maternal Abs present
1. Live-attenuated vaccines
2. Gene based vectors




Goal: Prevent severe complications
Challenges: To achieve the clinical end point is 
not easy; FI-RSV enhanced respiratory disease 
history
4. Gene based vectors
5. Live-attenuated vaccines




Goal: Po provide protection from infections and 
complications
Challenges: Lot of previous infections can 
decrease response to vaccine; necessary to boost 
up protection provided by natural infection; 
absence of indicators for severity of disease, 
diagnosis difficult
7. Subunit proteins having 
adjuvant
8. Gene based vectors having 
subunit proteins




Goal: To prevent transmission from mother to 
infants, maximize the protection of infants
Challenges: Lot of previous infections can 
decrease response to vaccine, necessary to boost 
up the antibody level for protection of infants
10. Subunit proteins in combina-
tion with standard adjuvants
11. Vaccines having virus like 
particles with adjuvants
Table 1. 
Key target groups for vaccine candidates.
79
Hurdles in Vaccine Development against Respiratory Syncytial Virus
DOI: http://dx.doi.org/10.5772/intechopen.87126
glycosylated G protein is responsible for viral attachment to the cell. The F protein 
not only contributes to binding of the virus to cells, but also plays a crucial part dur-
ing entry of virus by mediating fusion of the viral envelope with the cell membrane, 
thereby allowing deposition of the viral genome into the cytosol [8]. Besides this, F 
protein is a mediator of syncytium formation [5]. The function of the SH protein, 
which is mostly found in the infected-cell membrane, is unknown [9]. Other viral 
structural proteins are the nucleocapsid protein (N), the matrix protein (M), the 
phosphoprotein (P), the RNA-dependent RNA polymerase (L) and the M2 gene 
product M2-1: all these proteins are located inside the viral particle. Whereas the 
M2-2 gene product is packaged in the virion is currently unknown [10]. The function 
of the matrix (M) protein is to connect the viral nucleocapsid with the lipid envelops 
and it is also responsible for viral particle assembly. The M2-2 protein is involved in 
regulation of viral transcription [11]. M2-1 functions as transcription-elongation 
factor [12]. The phosphoprotein (P) and nucleocapsid protein (N) are essential for 
transcriptional activity, while the L protein has RNA polymerase activity.
3. Epidemiology
RSV infections have a distribution worldwide. These infections are more com-
mon during the winter season in temperate climates. However, RSV infections may 
occur throughout the year in tropical climates, but can be more frequent in the 
Figure 1. 
Schematic representation of the RSV virion and its genome composition (adapted and modified with 
permission from [6]).
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monsoon season in some areas [13–15]. Although infection can be established in 
several laboratory animals, however, natural infection with RSV appears to be lim-
ited to apes and humans [16]. RSV transmission occurs via direct contact or con-
tact with contaminated surfaces that harbor respiratory secretions. The virus can 
survive for many hours on toys or other substances, which explains the high rate of 
nosocomial RSV infections particularly in pediatric wards. The incubation period 
for RSV infection ranges between 2 and 7 days [17]. Almost 70% of newborns are 
infected in the first year of their life. By the age of 2 years, almost all children have 
been infected and over 50% will have been infected twice [18]. RSV infections are 
common in the population and re-infections probably occur frequently. In a study 
conducted by Hall et al., 1991, almost 25% of adult volunteers could be re-infected 
with RSV of the same group, 2 months after a natural infection [19].
RSV infection is the major source of severe respiratory illness in infants and 
young children and is the most frequent cause of hospitalization of infants and 
young children in industrialized countries [20]. RSV infections differ in disease 
severity, from a mild cold to bronchiolitis or pneumonia. Almost 3% of infants 
infected with RSV need hospitalization due to respiratory failure and feeding 
problems [21]. Among the hospitalized infants, 20% need mechanical ventilation 
[22]. The highest morbidity of RSV disease is seen in children under the age of 
6 months [23] and in children with associated risk factors such as prematurity, 
broncho-pulmonary dysplasia, congenital heart disease with increased pulmonary 
circulation or immune deficiency [24–27]. According to WHO estimates, RSV 
disease burden is ~64 million cases and 160,000 deaths per year worldwide. In USA, 
about 85,000–144,000 infants are admitted to hospitals with RSV infection annu-
ally which corresponds to 20–25% of pneumonia cases and about 70% bronchiolitis 
cases in the hospital [28, 29]. The elderly people are also at risk for extreme RSV 
disease and almost 14,000–62,000 RSV-associated hospitalizations of the elderly 
occur in USA with an approximate annual cost of RSV pneumonia-related hospital-
izations of $150–680 million [30, 31].
4. Pathogenesis
After RSV infection, virus primarily multiplies in the epithelial cells of the naso-
pharynx [32]. The exact mechanism by which RSV spreads to the lower respiratory 
tract is not clear yet. Currently, it is not known why the disease progression is mild 
in most children, but severe in a small subgroup. Different studies have described 
associations between disease severity and genes involved in allergic responses, like 
IL-4 and IL-4 receptor genes, and genes for inflammatory cytokines, e.g., IL-6 
and IL-8 [33]. Furthermore, up-regulation of chemokines during RSV infection is 
associated with disease severity. For example, CCL11 (eotaxin), RANTES (CCL5) 
and MIP1α have been found in higher levels in cases with more severe RSV infection 
and ERD [34, 35].
Several other factors could be associated with disease severity, for example, 
environmental factors, patient intrinsic factors, virus strain and viral load. 
Environmental factors like a high number of siblings, attendance of day-care centers 
and socio-economic status can enhance the chance of early exposure and may 
increase the risk of developing lower respiratory tract disease [36]. Other factors like 
geographical area, parental smoking and the use of wood-burning stoves have also 
been linked to an enhanced risk of severe RSV infections [37–40]. Patient-intrinsic 
factors like a compromised respiratory function, e.g., bronchopulmonary dysplasia 
(BPD) [25], or congenital heart disease with increased pulmonary circulation may 
significantly enhance the risk to develop severe RSV infection [41]. It is reported 
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in some studies that RSV-strain A is responsible for more severe disease [42], 
while other studies report no difference between RSV A and B strains [43, 44]. 
Furthermore, the course of lower respiratory disease was found to be associated with 
a high viral load [45]. Finally, RSV-specific immunity induced by vaccination may 
also be involved in immunopathological mechanisms leading to enhanced disease. 
This hypothesis is mainly based on experimental animal data [46], and on observa-
tions from a clinical trial where, as indicated above, infants were vaccinated with 
FI-RSV vaccine, which resulted in enhanced respiratory disease (ERD) upon natural 
infection [47–49]. The notion that inactivated-RSV preparations can prime for ERD 
is one of the factors that has delayed the development of an effective RSV vaccine.
5. Therapeutic approaches against RSV
Only supportive treatment is available. In supportive treatment we can use 
corticosteroids, bronchodilator and oxygen supplement. These are effective to some 
extent [50]. It is viral infection, so the use of antibiotics is not recommended, but 
according to some studies antibiotics can be used to some extent but not regularly 
to prevent the secondary bacterial infection such as urinary tract infections [51]. 
Corticosteroids also cannot be used routinely because they are the immunosup-
pressors [52]. The only recommended antiviral RSV treatment at clinical level is 
ribavirin. Studies are present which indicate the conflicting results of ribavirin use. 
It is also less effective and very costly. Due to the conflicting results of ribavirin, 
American Academy of Science recommendation is that ribavirin should not be 
routinely used in children having the symptoms of bronchiolitis [53]. Ribavirin 
completes its function by preventing the polymerase of virus. So ribavirin can 
inhibit both the DNA and RNA viruses. Ribavirin action may result in anemia 
and other adverse reactions such as hypersensitivity. According to few studies, 
ophthalmologic disorders also have been noted after the use of ribavirin. All these 
side-effects lead towards the limited use of ribavirin in RSV treatment [54]. A study 
indicated that ribavirin might be used in target groups such as children having RSV 
infection with comorbid immunosuppression, but it is necessary to investigate and 
verify more data about its recommendation [55, 56]. It has also been noted that 
once the disease has occurred, no effective treatment is available for preventing the 
disease. Another study explained its failure in treatment describing that inhibiting 
the replication of virus alone is not enough to block the virus mediated pathogenesis 
in host. So, due to limited treatment options and high disease burden, it is necessary 
to discover the new treatment as well as prophylactic policies.
Now there is focus on F protein for the development of anti-RSV drugs as well 
as vaccines. Researches are being conducted for the development of numerous 
antiviral drugs and antibodies that are in preclinical development stage. Some of 
the new vaccine and drugs are in evaluation stage. Experiments were conducted on 
cotton rats and mice in which RSV F specific nano-bodies and immunoglobulin were 
administered by intranasal route. This led to reduction in lung inflammation and also 
decreased the virus replication after RSV infection [57]. The RSV G protein is also 
being targeted for the development of drugs, prophylactic agents and vaccines. The 
RSV G protein consists of CX3C motif and is homologous in structure with CX3CL1 
[58]. RSV G protein increases the infection rate by binding the receptor CX3CR1. 
Experiments have shown that anti- RSV G monoclonal antibodies have the ability 
to block the interaction between RSV G CX3C-CX3CR1. This interaction inhibition 
decreased the lung inflammation. Experiments conducted on rats also have been 
shown that RSV G monoclonal antibodies have the greater ability to decrease the pul-
monary inflammation when compared with anti-F monoclonal antibodies [59–61].
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6. Current status of RSV vaccine
At present, there is no approved vaccine is present in the market which can 
protect from RSV infection. Due to increased burden of disease, it is essential to 
develop a vaccine that can give protection against the disease [47]. Recently, a lot of 
RSV vaccine candidates have been emerged using a variety of advanced technolo-
gies. About 60 RSV vaccines candidates targeting the pediatric and older popula-
tions are in development stage and some are also in preclinical stage [62]. According 
to a study, 16 RSV vaccine candidates are in clinical development stage [62].
6.1 Live attenuated vaccine
During 1960s, after the failure of formalin inactivated RSV vaccine (FI-RSV), 
struggles were started to develop live-attenuated vaccines candidates. By serial 
passaging of RSV A2 strain at lower temperature, live attenuated vaccines were 
produced; however, it was hard to achieve the balance between immunogenicity 
and safety [62].
Today, a lot of the cold passage (cp) and temperature sensitive (ts) vaccines have 
been produced. Evaluation of one cpts-248/404 was done in 1–2 month old aged 
infants. But it led to the problem such as congestion of upper respiratory tract and 
so, it was not followed for more investigations. After this struggles were done to 
attenuate the cpts-248/404 strain and many mutants were produced. After evalua-
tion these generated mutants were found to be over or under attenuated [63].
There is another live-attenuated type RSV vaccine which includes M-2 gene 
deletion is being tested on nonhuman primates. The M-2 gene regulates the transi-
tion from transcription to RNA replication. Studies have shown that by the dele-
tion of M-2 gene, viral RNA replication is decreased but at the same time G and 
F protein expression is increased through transcription which means that virus is 
attenuated at adequate level and may lead to neutralizing antibody response [64].
NS2 is another target gene for producing live attenuated vaccine RSV NS2. 
gene increases the shedding of epithelial cells and reduces or inhibits the antiviral 
cellular type 1 IFN induction and IFN response of the host. Vaccines which include 
the deletion of NS2 gene are stable genetically and sensitive to temperature to some 
extent [65, 66]. SH gene also has been considered for deletion for the live attenu-
ated vaccines. It is believed that SH gene is involved in viral fusion. According to 
few studies, it is involved in the inhibition of apoptosis by blocking the TNF- alpha 
pathway. To obtain the sufficient attenuation level to get the safety is the major 
continuing problem for live attenuated RSV vaccine [65–67].
6.2 Subunit vaccines
RSV G and F glycoproteins lead to the induction of neutralizing antibodies. 
These have been evaluated as potential vaccine candidate [68]. Subunit vaccines 
have the potential to be used for maternal immunization. They are also useful candi-
dates for elderly immunization. A number of subunit vaccines have been evaluated 
recently. The vaccines which are in clinical trials are co-purified G, F and M pro-
teins; purified F glycoprotein (PFP-1, PFP-2 and PFP-3); and BBG2NA etc. [69–76].
RSV PFP-1, PFP-2 and PFP-3 are the candidates which have been evaluated in 
children of >12 months of age and also in elderly target populations. These vaccine 
candidates consist of purified glycoprotein which are adsorbed to Al(OH)3 (PFP-1 
and PFP-2) or AlPO4 (PFP-3). These candidates were sufficiently tolerated by the 
target populations but acute reactions were also observed up-to minimum level. 
There was no observation of enhanced disease occurrence [70–77].
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7. Challenges to RSV vaccine development
7.1 Early age when immature immune system of neonates
The most noteworthy risk group for extreme RSV infection is infants under a 
half year of age [78, 79]. Practically speaking, first dose should be administered at 
the age of 2 months. Full term newborn children obtain maternal antibodies during 
the latter 50% of gestation and levels of antibody remain moderately high for a half 
year after the birth [80]. This would interfere when RSV vaccine would be done 
[81]. So there is need of an ideal vaccine which will not interfere with the maternal 
antibodies and will give protection in the presence of maternal antibodies. A few 
investigations show that newborn children under the age of 8 months have a less 
serum counter acting agent (antibody) response to characteristic RSV disease as 
compared to elder ones [82]. A less developed immune system may be the reason 
of this reduced immunity level, but maternal antibodies may also suppress the 
immune response [83].
Recent schedule for hepatitis B, diphtheria, rotavirus, pneumococcus, pertus-
sis, tetanus, Haemophilus influenzae type b and poliovirus show that vaccine for 
these infectious diseases will be done ideally after birth at 2, 4 and 6 months of 
age. Vaccination for RSV should be ideally administered at 6 months of age, so it 
is necessary and important to make sure that RSV vaccine should not interfere the 
working and efficacy of other routinely used vaccines during the childhood [84].
7.2 Induction of low affinity neutralizing antibodies
RSV vaccine was developed shortly after it was isolated. In 1960, FI-RSV 
vaccine was injected by intramuscular route in 2–7 months old infants and 
children. Instead of providing protection against wild type RSV infection, 
FI-RSV enhanced the respiratory disease development following wild type RSV 
infection during the subsequent RSV season. Lungs of children and infants with 
enhanced diseased were rich with large numbers of eosinophils and this was 
not found in patients of natural infection with RSV. After this disastrous out-
come, there was need to develop a safe RSV vaccine including the evaluation of 
enhanced disease [47–49, 85, 86].
These different immunopathology aspects which were seen in humans after 
FI-RSV vaccine and enhanced disease were later studied in non-human primates. 
In newborn macaques which were FI-RSV vaccinated and then infected with RSV 
virus, enhanced disease with increased level of eosinophils and neutrophils were 
seen [87–91]. FI-RSV produced the increased level of ELISA titer RSV antibody 
because it was highly immunogenic, but the provoked antibodies were non-neu-
tralizing. Antibodies produced did not provide the protection against virus because 
it could not prevent the fusion of virus [92, 93]. FI-RSV induced resulted RSV 
antibodies were also known to be of decreased avidity and this may be the result of 
having lack of maturation [94–97].
7.3 Lack of appropriate animal models
No ideal animal model for RSV vaccine is present which can be used for its 
evaluation. African green monkey kidney cells (Vero cells) were used for produc-
tion of RSV. High titers of RSV were observed on Vero cell line. Similar results were 
obtained when grown on human cells (HEp-2). On both these cell lines, RSV infec-
tion led to syncytia formation. These cell lines were used extensively to characterize 
the live attenuated RSV vaccines. In recent studies, there are reports that NHBE 
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(normal human bronchial epithelial) and HAE (human airway epithelial) cells are 
used to create model human nasopharyngeal mucosa. RSV infection did not show 
any pathological sign and also not led to syncytia formation on NHBE and HAE cell 
lines [98, 99].
Experiments to study attenuation of live attenuated RSV vaccine were also 
conducted on BALB/c mice, found permissive to infection to some extent. 
Advantages for mouse studies are that reagents are readily available which can 
be used for measurement of infection immune correlates [99–104]. Several non-
human primates act as host for RSV. RSV can replicate in the nasopharyngeal tract 
of their host. Macaques, African green monkeys, Chimpanzees and bonnet mon-
keys have been used to model RSV infection [105–112]. Relative viral titers of live 
attenuated RSV vaccines compared to wild type RSV disease can also be measured. 
Chimpanzees are the only non-human hosts which develop and show the clinical 
sign and symptoms of coryza following RSV infection. They are much permissive 
to RSV infection. So they are used for evaluation of comparative level of attenua-
tion among vaccines which are candidates in humans. But it has been shown by the 
recent studies that chimpanzee is not completely predictive of attenuation in young 
newborns. They are also scare and expensive. Study conducted by Karron et al. 
showed that those RSV vaccines sensitive to temperature and also had high degree 
attenuation in chimpanzee, were able to produce infection in lower respiratory tract 
in children [112].
7.4 Absence of RSV disease liability data and commercial risk
It is known that those children and persons primed with RSV are not at risk to 
RSV enhanced illness, but the absence of enhanced disease illness in RSV primed 
persons does not support the prediction that it will not be present in RSV naïve 
population. So it is very difficult to build up safety data which can support and be 
used for testation of novel RSV vaccine in newborns having age <6 month which is 
primary target population [113, 114]. There is absence of information (data) on RSV 
related mortality. This has prevented exact appraisal of the expenses and advan-
tages of RSV vaccines and prioritization of vaccines for various target populaces 
[49]. Lack of information on disease liability data is a big problem in less developed 
countries where mortality cases are concentrated [115].
7.5 Limited resources
Clinical investigations of applicant vaccines in the target populace are funda-
mental to figure out which vaccines ought to be created for licensure, yet these 
examinations are tedious and costly, what’s more, assets for these investigations are 
restricted. Measurement of impact of vaccine on disease in all target populations is 
very difficult and problematic. It is easy to diagnose RSV infection in infants and 
children because their respiratory secretions have high titers of RSV and so are easy 
to detect. Titers of virus in adults are low and sensitive RT-PCR assay is used for 
detection purpose. If there is a decrease in severity of disease, it is a good indication 
of vaccine being effective. Measures done for disease severity are not accurate at 
all ages of target populations. So there is need that larger and most costly studies 
should be performed [116].
7.6 Emerging RSV variants/mutation in RSV genome
RSV is divided antigenically into two groups which are RSV-A and RSV-B.  
These groups are further divided into genotypes as well as variants. It has been 
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investigated that different viruses belong to these different groups; genotypes as 
well as variants co-circulate in epidemics. So it is very difficult to develop an effec-
tive vaccine due to the presence of virus antigenic diversity as well as variability. 
Like other RNA viruses, RSV has high nucleotide substitution rate (10−3–10−4). 
Spontaneous type of deletions of G and SH genes have been studied in vitro. RSV 
genome encodes 11 proteins; one of them is G protein which is most variable having 
2 hypervariable regions. G protein has been investigated to accumulate amino acid 
changes periodically. RSV genotypes having the amino acids duplications in G 
proteins also have been isolated.
7.7 Disruption of antigenic epitopes
Researches had shown that formalin inactivation caused the alterations in 
the epitopes of the G and F proteins and as a result non-neutralizing antibodies 
were developed which led to formation of immune complex in the lungs [57, 69]. 
Recent studies have shown that changes in the properties of F protein occur during 
interaction of virus and host cell. The pre fusion (pre-F) which is highly energetic, 
transitions irreversibly into post fusion (post-F) form which is low energetic and 
stable, this occurs during insertion process of virus into host cell membrane. By this 
process, fusion of virus to host occurs. Although pre and post F are not structur-
ally similar, they share 2 antigenic regions. Neutralizing antibodies target these 
antigenic regions. Pre F also has 3 other antigenic sites not present in post-F. These 
sites are neutralization sensitive [68–72]. It is investigated that pre-F conformation 
changes to post-F conformation during the mechanism of formalin as well as heat 
inactivation and this change is irreversible. As a result of this change, complete 
loss of epitopes occurs. So this process explains the one of the reasons for failure of 
FI-RSV [69, 71].
7.8 Older age when immune-senescence of the elderly people
Elder target population group possess a considerable disease burden. The elder 
group has preexisting immunity, which makes it inconvenient to increase the 
existing immunity. Furthermore immune-senescence may lead to decrease in the 
efficacy of vaccine [116]. Immune-senescence is a challenge for proper vaccination 
in older target populations. RSV disease burden increases in elderly people in pres-
ence of underlying diseases such as cardiac and pulmonary conditions. Live attenu-
ated vaccines are found not to be immunogenic in elderly people. So now focus is on 
subunit vaccines for this target group [115, 117].
8. Future horizons in RSV vaccine and RSV therapeutics
• Continuous struggles are going on for the development of effective and 
safe RSV vaccines for each target group (infants, children, elders including 
pregnant women). Previous struggles made to build up a safe vaccine were 
failed. High antibody production was seen by the use of FI-RSV vaccine in 
1960. However, unfortunately vaccinated children developed a severe disease 
after administration of FI-RSV vaccine. Difficulties and barriers associated 
with vaccine development particularly live attenuated vaccine are enhanced 
respiratory disease, maternal antibodies, nasal congestion, low immunogenic-
ity, genetic variability and instability, immature immune system of infants, 
vaccine virus transmission and immune-senescence as well as preexisting 
immunity in elders. However, these problems are being slowly overcome [118].
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• Major achievements in last 3 years are that nanoparticle based vaccines and live 
vector vaccines have been investigated in different phase 1 and phase 2 trials 
and efficient results obtained. These vaccines step forward into later phase 
trials for evaluation [119]. So, there is hope that safe and well tolerated vaccine 
candidates will provide a long lasting immunity to all target groups, may be in 
our hands with in ~5–10 years.
• In vitro tissue culture system has been developed, that are being used for 
predicting the efficacy and safety of candidate vaccines.
• Palivizumab is only the success which is available to clinicians and is being 
used to reduce the burden of RSV. Palivizumab has decreased hospitalization; 
however, its use is limited due to high cost. There is hope that this approved 
prophylactic approach will be available to everyone and may soon come into 
extensive and widespread use. Palivizumab is patent of MedImmune and this 
patent is near to expire. So with expiry of this patent, there is hope that a cost 
effective palivizumab version will be developed. A recent technology hub has 
been established by the World Health Organization (WHO), the purpose of 
this is to increase the production of biosimilar versions [120]. There is hope 
that these products will be available in the market at low and affordable cost. 
These good initiatives will greatly reduce the mortality rates caused by RSV in 
developing world.
• Oral antivirals such as GS-5806 and a nucleoside analogue ALS-008176 have 
been passed through trials and they significantly decreased the replication 
of virus in human controlled experiments [121]. Nanobodies (single domain 
antibodies) has also been developed that protected the mice from infection and 
now are ready for clinical development. These results renewed the hope that an 
effective antiviral treatment for different risk populace will be on the horizon 
in next few years [57].
9. Conclusions
One of the most common causes of the respiratory tract diseases is the RSV 
affecting infants, young children and the elderly people. Only supportive treat-
ment is available such as corticosteroids, bronchodilators, oxygen supplement and 
ribavirin etc. which may not be occasionally effective. Palivizumab has decreased 
hospitalization; however, its use is limited due to high cost. Despite it is the era 
of progress and technology, no RSV licensed vaccine is available in the market to 
prevent RSV infection. Natural infection also provides partial immunity. A suc-
cessful vaccine candidate will provide the long term protective immunity and must 
not lead to induction of enhanced RSV disease. For RSV vaccine development 
different target groups are being considered such as elders including pregnant 
women, children and infants. Each of these target groups has different challenges 
for vaccine development. Maternal antibodies, enhanced disease and immature 
immune system are the major barriers for vaccine development in the infants. The 
children >6 months of age have more mature immune system than infants but still 
can be at the risk of enhanced disease from non-live RSV vaccine. For elderly target 
population immune-senescence as well as pre-existing immunity is the barrier for 
vaccine development.
An ideal RSV vaccine should be safe, well tolerated and provide long last-
ing immunity as compared to natural infection against both RSV strains A and 
87
Hurdles in Vaccine Development against Respiratory Syncytial Virus
DOI: http://dx.doi.org/10.5772/intechopen.87126
B. Further, it is recommended that separate vaccines should be developed for each 
target group. The tools that ought to enable us to build up a sheltered and successful 
RSV vaccine are accessible and our challenge is to utilize them wisely. We trust the 
suggestions for vaccine advancement noted above can support researchers, subsi-
dizing offices, and industry center their endeavors and assets most productively 
and viably.
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